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Abstract
The Cys loop receptors, a family of ligand-gated ion channels, mediate fast synaptic
transmission throughout the peripheral and central nervous systems.  These are large
multisubunit proteins, whose primary function is to transduce a chemical signal, binding
of a neurotransmitter, into an electrical signal, ion flux across the cell membrane.  These
receptors have been implicated in several disease states and represent major therapeutic
targets.  The work presented in this thesis focuses on the chemical-scale elucidation of
Cys loop receptors.  The main approach of this work is the structure-function study using
in vivo nonsense suppression methods.  This technique allows for the site-specific
incorporation of an unnatural amino acid into a protein expressed in a living cell.
Nonsense suppression methods were used to incorporate a series of fluorinated
tryptophan derivatives into the binding site of the 5-HT3R.  This study identified a
cation-? interaction between Trp 183 and the neurotransmitter, serotonin.  A similar
study using fluorinated phenylalanine derivatives identified a cation-? binding site at Tyr
198 in the GABAC receptor.  These studies build on previous work from our research
group and provide further evidence that the cation-? interaction is a common feature in
ligand recognition by Cys loop receptors.
Nonsense suppression was also used to examine the role of several tyrosine
residues in the 5-HT3R.  Here the findings demonstrated that the side chains of Tyr 143
and 153 make functionally important hydrogen bonds.  These data were used to refine
several computational models of serotonin docked into the binding site.
Structure-function studies of two conserved prolines in the M2-M3 loop showed
that this region of the receptor is involved in the conformational changes associated with
viii
receptor activation.  The data also provide preliminary evidence that Pro 308 may serve
as hinge for the gating movement of the M2 helix.
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1Chapter 1. Introduction
1.1 Chemistry and the brain
In terms of speed and complexity, the nervous systems of higher organisms likely
represent the pinnacle of intercellular communication.  The human brain alone has
roughly 1012 neurons and each neuron typically makes 103-104 connections or synapses
with other neurons.  This means that there are approximately 1015-1016 synapses in the
human brain, with each synapse representing an intercellular connection for
communication between two neurons.  Thus, on one level, the brain is essentially a vast
network for cell-to-cell communication.  Astonishingly, signaling in this massive
synaptic network operates on the millisecond timescale.  It is this speed and complexity
that gives rise to human thought and consciousness.  An amazing feature of intercellular
communication in the nervous system, and ultimately thought and consciousness, is that
the events governing their function occur at the molecular level.
The primary mode of synaptic transmission (interneuronal communication) in the
nervous system is chemical.  In other words, the information conveyed between neurons
is encoded in a small molecule, the neurotransmitter.  This is recognized and bound by
specific receptor molecules that translate the chemical information into cellular
processes.  The presynaptic neuron initiates synaptic transmission by releasing a
neurotransmitter into the synaptic cleft.  The neurotransmitter diffuses across the cleft
where it binds to a neuroreceptor embedded in the membrane of the postsynaptic neuron.
Binding of the neurotransmitter activates the receptor, conveying the synaptic signal
across the cell membrane and resulting in the modulation of the postsynaptic neuron.
2There are a wide variety of neurotransmitters and many different neuroreceptors.
The majority of neuroreceptors can be divided between two main classes: the G-protein
coupled receptors which mediate slow synaptic transmission and act through second
messenger pathways, and the ligand-gated ion channels (LGIC) which mediate fast
synaptic transmission.  In LGICs, binding of the neurotransmitter induces a
conformational change in the protein, opening an ion permeant channel that spans the cell
membrane.  The ion channel is fully contained within the LGIC, and once open, ion flow
through the channel alters the postsynaptic neuron’s membrane potential.  This then
either encourages or discourages the firing of an action potential in the postsynaptic
neuron, depending on whether the LGIC is excitatory (cation selective) or inhibitory
(anion selective).
The primary goal of the work presented in this thesis is the chemical-scale
elucidation of the structure and function of LGICs.  In particular, the studies focus on
elucidation of a serotonin-gated ion channel, the 5-hydroxytryptamine-3 receptor
(5-HT3R)
1, a member of the Cys loop family of LGICs.  This family of receptors
mediates fast synaptic transmission throughout the peripheral and central nervous
systems.  They are also the targets for therapeutic treatments of Alzheimer’s disease,
Parkinson’s, disease, schizophrenia, stroke, learning and attention deficit disorder, and
drug addiction.  The motivations for these studies are twofold.  The Cys loop receptors
are biologically and therapeutically significant, and they are of fundamental interest from
a chemical perspective.  Their study addresses important concerns in drug-receptor
interactions and molecular recognition, and the structural rearrangement associated with
activation of the ion channel poses an intriguing chemical question: How does the
3noncovalent binding of a small molecule induce a large conformational change in a
multisubunit protein?
1.2 The Cys loop family of ligand-gated ion channels
In addition to the 5-HT3R, the Cys loop family of LGICs also includes the nicotinic
acetylcholine (nAChR), gamma-amino butyric acid A (GABAA), GABAC, and glycine
(GlyR) receptors.2-8  These receptors can be separated into two subclasses based on their
ion permeation properties: the cation-selective receptors including the nAChR and 5-
HT3R, and the anion-selective receptors including the GABAA, GABAC, and GlyR.  The
best-studied member of this family is the nAChR.  These receptors are quite homologous
with 25-30% conservation in the amino acid sequence identity among the various
members.  Thus, much of what is known about the structure and function of these
receptors is inferred from studies of the nAChR.
The Cys loop receptors are multisubunit integral membrane proteins.  Their
quaternary structure is pentameric with five homologous subunits arranged in a
pentagonal array around a central pore (Figure 1.1).  Each subunit has a large
extracellular N-terminal domain and four transmembrane domains, M1-M4.  The M2
domains of each subunit line the interior of the channel lumen.  The extracellular domain
contains the ligand-binding site, as well as the Cys loop.  The latter is a loop formed by
two disulfide-bonded cysteines and is a common structural motif in all members of the
family.  Each receptor in the family has a variety of subunit isoforms.  These combine in
different compositions to form distinct receptor subtypes.  For most of these receptors the
exact subunit composition is unknown.  The muscle receptor of the nAChR, however, has
a well-understood composition of (?1)2?1?? (Figure 1.1).   In this receptor, the ligand-
4binding sites are located primarily in the ?-subunits, and it is known both must be
occupied to optimally activate the receptor (i.e., open the ion channel).  For the 5-HT3R,
three subunits have been identified; A, B, and C.1, 8, 9  The subunit stoichiometry for native
receptors has yet to be determined, however, A subunits can form functional homomeric
receptors, indicating that as with the muscle nAChR, the A subunit contains the majority
of the ligand-binding determinants.
Being integral membrane proteins, the Cys loop receptors have been resistant to
characterization by high-resolution structural techniques such as NMR and x-ray
crystallography.  A significant source of structural information concerning these
receptors has come from cryo-electron microscopy (cryo-EM) studies on the Torpedo
electric ray.  The electric organ in these rays is highly enriched in nAChR-containing
membranes.  The high density of nAChR in this tissue is amenable to structural analysis
by cryo-EM.10-13  Recently, cryo-EM studies by Nigel Unwin have produced an image of
the transmembrane domains at 4-Å resolution (Figure 1.2a).14  This represents the highest
resolution structure of this region of the protein, and is supported by much of the earlier
structure-function studies in the Cys loop receptors.  The structure revealed that each
transmembrane domain forms a membrane-spanning ?-helix.  In addition, it provided
strong evidence that the gate of the receptor is formed by the hydrophobic side chains of
Leu 9’ and Val 13’ in M2 (numbering convention for residues in M2 starts with 1’ at the
C-terminal or cytoplasmic end of M2), confirming results from previous studies.15, 16  A
novel feature of this structure was the clear indication that the M2 domain extends two
helical turns above the extracellular membrane.  This contradicts the predictions based on
5the hydropathy profile of the nAChR subunits, but results from earlier substituted
cysteine accessibility studies support this conclusion.17
Unwin, Phil T Soc B, (2000) 335.
Out
In
membrane
Cys Loop
(b) (c)
Channel
120 Å
70 Å
Binding site
(a)
Figure 1.1.   Structure of Cys loop LGICs.  (a) Cartoon of the nAChR showing
general structural features of the receptor.  Inset shows the location of the binding
site at the subunit interface and the loops that contribute important aromatic
residues to the primary binding site.  (b) 4.6 Å cryo-EM of the nAChR.  (c) Single
subunit showing subunit topology.
6While as yet, no x-ray crystal structure exists for these receptors, there is a crystal
structure of an acetylcholine binding protein (AChBP) (Figure 1.2b).18-20  This is a soluble
protein from the snail, Lymnaea helicalis, and is highly homologous to the extracellular
domain of the nAChR.  The crystal structure of this protein has been a watershed event in
the study of Cys loop LGICs, providing the first high-resolution structural data on the
ligand-binding site.  This structure confirmed much of the previous biochemical and
biophysical studies on the nAChR, including the location of the ligand-binding site at
subunit interfaces.  In the muscle nAChR, the two binding sites are located at the ?/? and
?/? interfaces (Figure 1.1a and Figure 1.2b).  Furthermore, the AChBP structure revealed
that the binding site is composed of five noncontiguous loops (loops A-E), each of which
contributes one or more aromatic residues to form the primary binding site (see chapters
2 and 3 for more details).
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Figure 1.2.  Cryo-EM structure of nAChR transmembrane domains and AChBP
structure.  (a) Top view (looking down from the extracellular side) of the
transmembrane domains based on Unwin’s 4.0Å images.  Leu 9’ for each subunit is
shown in CPK representation.  (b) Transmembrane domains of a single subunit.  (c)
Top view of the AChBP structure.  (d) Side view of AChBP with two subunits
highlighted and the binding site residues shown in ball-and-stick representation.
1.3 Unnatural amino acid mutagenesis
Although the recent structural breakthroughs detailed above have been invaluable
to the study of Cys loop receptors, there are still many outstanding questions concerning
8their function.  By their very nature, these receptors are dynamic proteins undergoing
large conformational changes and interconverting among multiple states (i.e., non-
conducting closed state to conducting open state).  X-ray crystal structures provide a
starting point for evaluating these processes, but are only static snapshots.  Structure-
function studies are still necessary to determine what features revealed by the crystal
structure are functionally significant.  The central approach of the research presented here
is the use of in vivo nonsense suppression for structure-function studies.  This method
allows for the site-specific incorporation of a synthetic amino acid into a protein
expressed in a living cell.  In many ways, this method is ideal for the study of ion
channels.  The ability to incorporate unnatural amino acids permits systematic structure-
function studies, furnishing a chemical-scale precision unique among biochemical
methods.  In addition, the methodology allows for study in a cellular system, obviating
the need for functional isolation of these multisubunit integral membrane proteins.  One
of the drawbacks of the nonsense suppression method (and in particular in vivo nonsense
suppression) is the limited quantity of protein produced.  This limitation is minimized,
however, in the study of ion channels due to the extraordinary sensitivity of modern
electrophysiology.  Thus, the functional consequences of the introduced mutations can be
readily assayed.
In 1989, Peter Schultz reported the first general method for the biosynthetic
incorporation of unnatural amino acids using nonsense suppression.21-24  The method
works by commandeering a non-coding codon or ‘nonsense codon’ (Figure 1.3a).  The
commandeered codon– usually a stop codon– is placed in the gene at the site of interest.
Typically, this would result in the premature termination of the protein’s biosynthesis.
9However, if the translation system is supplied with a suppressor tRNA (a tRNA whose
anticodon recognizes the nonsense codon) that is charged with a synthetic amino acid,
then translation proceeds with the unnatural amino acid incorporated into the protein at
the site of interest.  The in vivo nonsense suppression method extends this methodology
for in vivo usage with the Xenopus oocyte expression system.25-27
tRNA with
unnatural amino acid
mRNA with
STOP codon at
site of interest Protein with
unnatural amino acid
at site of interest
Ribosome
(a)
(b)
Figure 1.3.   Nonsense suppression method.  (a) Basic details of how nonsense
suppression works.  (b) In vivo nonsense suppression method.
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The basic method for in vivo nonsense suppression first entails the placement of the
amber stop codon (TAG) at the amino acid position of interest (Figure 1.3b).  This is
done using conventional site-directed mutagenesis, followed by in vitro transcription of
UAG containing mRNA.  Separately, a suppressor tRNA containing the appropriate
anticodon (CUA), is prepared and chemically acylated with an unnatural amino acid.
The tRNA and mRNA are then co-injected into a Xenopus oocyte.  Protein synthesis and
surface expression are carried out by the oocyte, allowing for electrophysiological study
24 to 72 hours later.
To date, more than eighty mutations (including both ?-amino and ?-hyroxy acids)
have been incorporated into 15 different integral membrane proteins (Figure 1.4).  In
addition, the method has been extended for use with mammalian expression systems.28  In
our experience, the method is amenable to two sorts of studies: 1) detailed structure-
function studies involving rational perturbation of the residue of interest29-31 and 2) the
introduction of unnatural side chains with novel chemical and biophysical properties such
as fluorescent probes, ‘caged’ residues, and tethered agonists.32-34 The limitations as to the
variety of unnatural amino acids that can be incorporated have never been rigorously
studied.  There is, however, anecdotal evidence that hydrophobic residues suppress better
than polar ones, and both D-amino acids and ?-amino acids are poorly incorporated, if at
all.  Having noted this, the method can accommodate a wide variety of side chains,
including several backbone mutations.35-38
11
H3C
H3C
H3C
CH3
H3C
CH3
H3C
H3C
H3C
H3C
H2C
H3C
CH3
H3C
CH3
H2
+
N
CO2
-
H2
+
N CO2
-
-O2C
-O2C
HO
HS
HS
HO
H3C
HO
X
NO2
NO2
S
MeO
HO
HO
HO
F
F
F
F
F
F
HO
HO
F
O
NO2
O
N
-O2C
-O2C
N
H
N
H
F
F
N
H
F
F
F
N
H
F
F
F
F
N
H
F
S
N
CH3
N NH
S
HN NH
O
N
H
O
ON
O
N
O
N
N
H
X
OH3N
ON
H2
N+
O N
H
O
H2
+
N
CO2
-
CH3
HO CO2H
CH3
HO CO2H
HO CO2H
F
F
F
F
F
HO
F
F
ON
O
ONH
N
HF
X = OH, F, Cl, Br, CH3, 
NH2, OCH3, CO2H,  
C(O)CH3, CH2C(O)CH3, 
OP(ONb)2
X = F, CN, CH3,
NH2, Br
HO CO2H
OH
HO CO2H
Se
NO2
S
HN NH
O
N
H
O
O
H
N
H3N
H2N CO2H HN CO2H
CH3
H2
+
N
CO2
-
H3C
O
CH3
H3C
O
CH3
HO
Figure 1.4.   Representative ?-amino and ?-hydroxy acids incorporated into
integral membrane proteins using in vivo nonsense suppression.
1.4 Structure-function studies
The nonsense suppression method is an excellent tool for structure-function studies.
Much like conventional mutagenesis, it allows for site specificity in the mutations to be
introduced.  However, unlike conventional mutagenesis, it is not limited to the standard
20 amino acids.  With the use of synthetic amino acids, one has rational control over the
mutations to be introduced.  In addition the chemical precision afforded by the technique
is unique among biochemical methods.  Consequently, it can provide chemical-scale
information on the functional role and structural context of a given amino acid.
The majority of the work presented in this thesis centers on structure-function
studies of the 5-HT3R.  Chapter 2 describes studies on the ligand-binding site in the
12
5-HT3R and nAChR in which a series of progressively fluorinated tryptophans is used to
identify the cation-? binding site of the 5-HT3R and to compare and contrast ligand-
recognition properties between the two receptors.  This work is largely based on a
Biochemistry paper written in collaboration with Gabriel Brandt, who performed all of
the experiments on the nAChR.39  The studies presented in Chapter 3 use a series of
tyrosine analogs to probe the role of tyrosine residues near the ligand-binding site in the
5-HT3R.  Results from these studies are used to assess several models in which serotonin
is computationally docked into the binding site.  This chapter is based on a Journal of
Neuroscience paper written in collaboration with the Sarah Lummis group at the
University of Cambridge.40  They performed all of the computational work, and Kerry
Price in particular, contributed significant effort to this project.  The work in Chapter 4
investigates the role of two conserved prolines in the M2-M3 loop of the 5-HT3R.  The
findings from this work support a recently proposed model for the functional role of this
loop in the gating pathway of Cys loop receptors.  This work represents as well a
collaboration with the Sarah Lummis group.  Finally, Chapter 5 includes three
miscellaneous studies:  investigations of Phe 226 (Tyr 190 in the nAChR) in the
‘aromatic box’ of the 5-HT3R; work identifying Tyr 198 (Trp 149 in the nAChR) as a
cation-? binding site in the GABAC receptor; and efforts towards the incorporation of a
backbone thioamide via nonsense suppression.  The first two studies in Chapter 5 were
done in collaboration with Sarah Lummis.
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Chapter 2. Cation-? interactions in ligand recognition by serotonergic
(5-HT3A) and nicotinic acetylcholine receptors
2.1 Introduction
Synaptic transmission is largely mediated by neurotransmitters and the receptors
that bind them.  At the core of this process is the selective recognition and binding of a
small molecule by its protein host.  Despite the pharmacological and clinical significance
of compounds that modulate synaptic signaling, the chemical basis of neurotransmitter
binding has been difficult to determine.  High-resolution structural data on neuroreceptors
with bound agonists are only just becoming available1-5, and functional data are still
needed to distinguish which agonist-receptor interactions are mechanistically significant.
Nearly all neurotransmitters contain a cationic center, and a common strategy for
biological recognition of cations is the cation-? interaction, the stabilizing interaction
between a cation and the negative electrostatic potential on the face of an aromatic ring.6, 7
Earlier work in the Dougherty group introduced a technique for the in situ identification
of cation-? binding sites.8  This technique relies on nonsense suppression methodology
for site-specific introduction of an unnatural amino acid into a functioning receptor
expressed in a living cell.9-12  In the first application of the technique, a series of
fluorinated Trp derivatives was introduced at various positions in the binding region of
the nicotinic acetylcholine receptor (nAChR).  At Trp 149 of the ?-subunit, the EC50 of
ACh for receptor activation was strongly correlated to the degree of fluorination,
providing a strong indication that ACh  binds to the nAChR through a cation-?
interaction with Trp ?149.  This assessment was subsequently confirmed in 2001 by the
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crystallization of a soluble acetylcholine-binding protein (AChBP) from the snail,
Lymnaea helicalis.2  AChBP shares significant structural and sequence homology with
the nAChR ligand-binding domain. (Figures 2.1 and 2.2)  The crystal structure of AChBP
revealed that the binding site is a box of aromatic residues, including the critical Trp
?149. (Figure 2.1)  Electron density corresponding to a molecule of HEPES was seen in
this box with its ammonium center bound to Trp ?149, as expected for a cation-?
interaction.
(a) (b) (c)
Trp143
Figure 2.1.   Several views of the nicotinic acetylcholine receptor (nAChR).  (a)
Details of the binding site illustrating the prevalence of aromatic residues.  The
coordinates come from X-ray diffraction of an ACh binding protein with high
homology to nAChR.  (b) The 'aromatic box' comprising the nAChR active site,
based on AChBP coordinates. (c) Diffraction data from AChBP showing a HEPES
molecule from the crystallization buffer bound to the face of Trp143, the homolog
of muscle nAChR Trp149 and 5-HT3AR Trp183.
In the work presented in this chapter, the Fn-Trp technique is utilized to examine
the ligand-binding domain of the serotonin-gated ion channel, 5-HT3AR.  In addition, the
cation-??interaction at the nAChR is further evaluated, considering nicotine and several
other agonists.  This work was done in collaboration with Gabriel Brandt who performed
the majority of nAChR experiments.  These studies generate two major findings.  The
first is that 5-HT3AR Trp 183, which aligns with Trp ?149 in the nAChR, binds the
primary ammonium of serotonin  (5-hydroxytryptamine, or 5-HT) via a cation–?
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interaction.  The second is that in the muscle nAChR, nicotine does not experience a
strong cation-? interaction with Trp ?149.  The first result is consistent with the idea that
the binding site of the serotonin channel is highly homologous to that of nAChR.  The
second result, however, is surprising in light of accepted pharmacophore models for the
nicotinic receptor.  Because of questions raised by these results, a series of both serotonin
and nicotine derivatives were analyzed to better understand the role of the cation-?
interaction in ligand recognition at these two receptors.
muscle       TWTYDGS----VVAI NPESDQPDLS-NFME SGEWVIKESRGWKHS VTYSCCPDTPYLDIT
5-HT3A       SWLHTIQDINISLWR LPEKVKSDRS-VFMN QGEWELLGVLP--YF REFSMESSNYYAEMK
AChBP        SWTHHSR----EISV DPTTENSDDSEYFSQ YSRFEILDVTQKKNS VTYSCCPEA-YEDVE
  PDLVLYNNADGDFAI VKFTKVLLQYTGHIT WTPPAIFKSYCEIIV THFPFDEQNCSMKLG
  PDILINEFVDVGKSP -NIPYVYIRHQGEVQ NYKPLQVVTACSLDI YNFPFDVQNCSLTFT 
  PDLAAYN-AISKPEV LTPQLARVVSDGEVL YMPSIRQRFSCDVSG VDTESG-ATCRIKIG 
muscle  
5-HT3A 
AChBP     
93
149 190 198
Figure 2.2.   Sequence alignment of muscle nAChR?, 5-HT3AR, and AChBP.  The
residues that comprise the aromatic box are indicated with arrows, with the
exception of the Trp residue contributed by the interfacial subunit, which is
conserved among all members of the nAChR receptor family and which is ?55 or
?57 in muscle nAChR and ?90 in 5-HT3AR.
2.2 Results
Unnatural amino acids were incorporated into the 5-HT3AR and nAChR using in
vivo nonsense suppression methods, and mutant receptors were evaluated
electrophysiologically.9-12  The structures and electrostatic potential surfaces of the side
chains of the unnatural amino acids utilized are presented in Figure 2.3.  Electrostatic
potential surfaces provide a useful guide for evaluating the cation-? binding ability of an
aromatic ring.13, 14  These surfaces show how electron-withdrawing groups such as cyano
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and fluoro substantially weaken the cation-? interaction.  The agonists used in these
studies are presented in Figure 2.4, along with their electrostatic potential surfaces.  Note
that the energy scales of the electrostatic potential plots are very different for Figures 2.3
and 2.4.  For the side chains, the scale is ±25 kcal/mol, such that red is negative and blue
is positive electrostatic potential.  However, the structures of Figure 2.4 are all cations,
and so the energy range is -5 to 160 kcal/mol.  For a cation, the surface is positive
everywhere; red simply represents relatively less positive, blue relatively more positive.
When studying weak agonists and/or receptors with diminished binding
capability, we found it necessary to introduce a Leu to Ser mutation at a site known as 9'
in the second transmembrane region of the receptor.15, 16  This site is almost 50 Å from the
binding site, and previous work has shown that each L9'S mutation lowers EC50 by a
factor of roughly 10, with multiple L9'S mutations having an additive effect.  Results
from earlier studies and data reported below clearly demonstrate that trends in EC50
values are not perturbed by L9'S mutations16.  For the present study, we used receptors
that contain one or two L9'S mutations, as noted in the Tables and Figure captions.
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Figure 2.3.   Side chains introduced in place of binding site Trp residues.  (a) The
series of fluorinated Trp analogs, with the gas-phase cation-??binding energy of
fluoroindoles (HF?6-31G**) in kcal/mol. (b) Trp analogs without the indole
nitrogen hydrogen bond donation ability, along with calculated cation-??binding
energy.  (c) Trp analogs for screening Trp sites for electrostatic interactions, with
calculated cation-? binding ability.  AM1 electrostatic surfaces are colored
according to an energy scale corresponding to ±25 kcal/mol, where blue is positive
and red negative.
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Figure 2.4.   Agonists utilized in this study  (a) nAChR agonists, with AM1
electrostatic surfaces calculated using Spartan showing the overall geometrical
similarity of the structurally distinct nicotinoid and cholinergic agonists.  (b)
5-HT3AR agonists, with AM1 electrostatic surfaces showing the varying charge
density around the nitrogen center.  Electrostatic surfaces correspond to an energy
range of –5 to +160 kcal/mol, where blue is positive and red negative.
Finally, it should be noted that the quantity reported here, EC50, is not a binding
constant, but a composite of equilibria for both binding and gating.17  An advantage of
EC50  is that it represents a functional assay; all mutant receptors reported here are fully
functioning ligand-gated ion channels.  This alleviates concerns that the mutations
introduced cause a massive structural reorganization of the receptor.  Because the subtle
mutations we make are in the region of the agonist binding site, and the presumptive gate
of the ion channel is almost 50 Å away, we assume variations in EC50 for the series of
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unnatural residues reflect differential agonist-binding ability, and that the gating
equilibrium is not substantially perturbed.
2.1.1 5-HT3AR Studies
Two subunits, A and B, have been identified for the 5-HT3R.
18, 19  Only the 5-
HT3AR when expressed alone in heterologous expression systems forms functional
homomeric receptors, and the 5-HT3R studies presented here were carried out using
homomeric 5-HT3A receptors.  Previous work has shown that the homomeric and
heteromeric (A and B) receptors share a common pharmacology while differing
somewhat in biophysical properties, such as conduction, kinetics, and desensitization
characteristics.20
2.1.2 Position 183 in the 5-HT3AR
Because of the well-established effect of fluorine substitution in modulating the
cation-? interaction, a series of fluorinated Trp derivatives (5-F-Trp, 5,7-F2-Trp, 5,6,7-F3-
Trp, and 4,5,6,7-F4-Trp) was incorporated at position 183, the analog of Trp ?149.
Whole-cell currents and fits to the Hill equation, presented in Figure 2.5, demonstrate that
these receptors display the functional hallmarks of 5-HT3R’s – desensitization to
prolonged agonist exposure and Hill coefficients around two.  The EC50 values for the
wild type and the mutants are given in Table 2.1.  A clear trend can be seen from the data.
Each additional fluorine produces an increase in EC50.  Re-introduction of the wild type
residue, Trp, yielded an EC50 of 1.21 µM, comparable to that obtained from the wild type
receptor heterologously expressed in oocytes.  If a single fluorine is added to the
tryptophan ring EC50 increases 5-fold to 6.03 µM.  Addition of another fluorine to the
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ring leads to a 31-fold increase (relative to wild type) in EC50, 37.7 µM, and a third
fluorine yields an EC50 of 244 µM, 201-fold greater than Trp.
232 µM 350 µM 465 µM 1000 µM 1250 µM155 µM
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75 nA
5,6,7-F3-Trp
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Figure 2.5.  Electrophysiological analysis of 5-HT.  (a) Representative voltage-
clamp current traces for oocytes expressing suppressed 5-HT3AR. Bars represent
application of 5-HT. (b) 5-HT dose-response relations and fits to the Hill equation
for 5-HT3AR suppressed with Trp (circles), F–Trp (squares), F2-Trp (diamonds), and
F3-Trp (triangles) at position 183. (c) Fluorination plot (log [EC50/EC50 (wt)] versus
calculated cation-? binding ability for the series of fluorinated Trp derivatives) for
5-HT (circle) at the 5-HT3AR and ACh (squares) at the nAChR. 5-HT data fit the line
y = 5.37 - 0.17x and ACh data fit the line y = 3.2 - 0.096x. The correlation for both
linear fits is r = 0.99.
Attempts to record dose-response relations from the incorporation of 4,5,6,7-F4-
Trp at 183 were unsuccessful because this mutant required highly elevated concentrations
of 5-HT— concentrations at which the agonist becomes an effective open channel-
blocker.  In a similar strategy to that used for the nAChR, a Val to Ser mutation was
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introduced at position 13’ in the M2 domain.  This mutation has been shown to increase
the agonist sensitivity of the 5-HT3R.
21, 22  The EC50 values for the Fn-Trp series did show
a progressive increase correlating with fluorination of the tryptophan ring, but did not
entirely replicate the trend seen for receptors lacking this mutation (Table 2.1).  Further
analysis demonstrated that this mutation leads to standing currents that are reversible by
addition of the open-channel blocker TMB-8, indicating this mutation produces
constitutive activation of the receptor in the absence of agonist.  For this reason, studies
with the V13’S mutation were abandoned.
As in previous work on the nAChR, our measure for the cation-? binding ability
of the fluorinated Trp derivatives is the calculated binding energy (kcal/mol) of a generic
probe cation (Na+) to the corresponding substituted indole.8, 13  This provides a convenient
way to express the clear trend in the dose-response data in a more quantitative way.
Extensive studies of the cation-? interaction establish that trends in cation-? binding
ability across a series of aromatics are independent of the identity of the cation, justifying
the use of a simple probe ion.  In order to also place the dose-response data for the
channel on an energy scale, the logarithmic ratio of EC50 for mutants to EC50 for wild
type is used.  We refer to such representations as fluorination plots.  A plot of this ratio
versus cation-? binding ability for Trp183 reveals a compelling relationship (Figure
2.5c).  Over a range of greater than two orders of magnitude in EC50, there is a linear
correlation between log (EC50) and the cation-? binding ability of the side chains.  This
provides substantial evidence that Trp 183 binds 5-HT through a cation-? interaction
arising from van der Waals contact between the agonist ammonium group and the indole
side chain.
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Table 2.1 Dose-response data for 5???3?R and unnatural amino acids
Along with modulating the cation-? interaction, fluorination also increases the
ability of a Trp analog to donate a hydrogen bond.23, 24  Therefore, an alternative
interpretation of the above results would be that the hydrogen-bonding ability of the NH
of the indole side chain of Trp 183 decreases receptor activation, and that fluorinated Trp
analogs decrease activation by increasing the hydrogen-bond strength.  This hypothesis
suggests that EC50 would be decreased by side chains that remove the hydrogen bond, but
Residue EC50±SEM (µM) Hill±SEM
W183
5-HT Trp 1.21 ± 0.06 2.0 ± 0.16
F-Trp 6.03 ± 0.5 1.4 ± 0.14
F2-Trp 37.7 ± 2.96 1.9 ± 0.23
F3-Trp 244  ± 8.4 2.5 ± 0.17
5-HT Trp 0.04 ± 0.002 1.6 ± 0.06
V13'S F-Trp 0.06 ± 0.003 1.8 ± 0.14
F2-Trp 0.27 ± 0.006 2.6 ± 0.13
F3-Trp 3.53 ± 0.141 2.2 ± 0.16
N-Me-5-HT Trp 1.82 ± 0.10 2.5 ± 0.13
F-Trp 2.70 ± 0.17 1.9 ± 0.19
F2-Trp 23.1 ± 2.73 2.6 ± 0.22
F3-Trp 368  ± 12 2.0 ± 0.10
5-HTQ Trp 1.07 ± 0.07 2.1 ± 0.25
F-Trp 1.65 ± 0.15 1.6 ± 0.19
F2-Trp 12.8 ± 0.95 1.8 ± 0.19
F3-Trp 284  ± 18.7 2.0 ± 0.15
5-HT 1-Np-Ala 30.4 ± 1.75 1.6 ± 0.10
2-Np-Ala 32.0 ± 2.30 1.6 ± 0.12
N-Me-Trp 25.6 ± 1.66 1.8 ± 0.16
W90
5-HT Trp 1.21 ± 0.06 2.0 ± 0.16
F4-Trp 1.01 ± 0.05 1.6 ± 0.09
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remain isosteric with Trp.  To test this hypothesis, a series of Trp analogs lacking a
hydrogen-bond donor at the nitrogen position of the indole was incorporated at position
183 (Figure 2.3b).  The EC50 values for 2-Np-Ala, 1-Np-Ala, and N-Me-Trp were 32?µM,
30?µM, and 26?µM, respectively (Table 2.1).  The increased EC50 is opposite to the
prediction of the hydrogen-bond hypothesis.  Thus, it appears that modulation of
hydrogen-bonding ability does not explain the increase in EC50 in response to
fluorination.
2.1.3 Position 90 in the 5-HT3AR
An important question is whether the dramatic fluorination effect seen at position
183 in the 5-HT3AR is unique to this site, as was observed for Trp ?149 in the nAChR.  In
principle, the cation could interact simultaneously with several sides of the aromatic box.
Based on sequence alignment and the AChBP structure, Trp 90— which aligns with Trp
?55/?57— forms part of the binding site in the 5-HT3AR.  Thus, 4,5,6,7-F4-Trp was
incorporated at position 90.  The EC50 value of this mutant was almost identical to wild
type, 1.1?µM and 1.2?µM respectively, indicating that Trp 183 uniquely defines the
cation-? binding site in the 5-HT3AR (Table 2.1).
2.1.4 N-Me-5-HT and 5-HTQ at the 5-HT3AR
Comparison of the fluorination plots for ACh and 5-HT shows that the slopes of
the lines are quite different for the two agonists.  The steeper slope seen for 5-HT
indicates its ammonium center is more sensitive to electrostatic attenuation of the face of
the tryptophan ring.  Given the strong electrostatic component of the cation-? interaction,
it is very likely this difference arises from the differing charge distributions between a
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primary ammonium (5-HT) and a quaternary ammonium (ACh).  To investigate this
relationship further, we attempted to serially modulate the strength of the cation-?
interaction by varying the degree of alkylation at the ammonium center.
Dose-response relations were recorded for the secondary serotonin analog, N-
methyl-5-hydroxytryptamine (N-Me-5-HT) and the quaternary derivative, N,N,N-
trimethyl-5-hydroxytryptamine (5-HTQ) with the fluoro-Trp series at position 183
(Figure 2.4b).  The results for these experiments are presented in Table 2.1.  Mono or tris
methylation at the ammonium center of 5-HT has a minimal effect on EC50; both agonists
are comparable to the natural ligand, serotonin.  At position 183 in the 5-HT3AR— as
with 5-HT itself— each additional fluorine substituent produces an increase in EC50,
indicating a significant cation-? interaction with the ammonium centers in both N-Me-5-
HT and 5-HTQ (Figure 2.6).
Surprisingly, the expected trend for the substituted agonists (primary more
sensitive than secondary, and secondary more sensitive than quaternary) is not seen.  It is
difficult to interpret these results, however, because in essence, these are double mutant
studies with both the receptor and the agonist being simultaneously altered.  It may be
that though all three are potent agonists and bind to Trp 183 via a cation-? interaction, the
binding mode for each is subtly different.  Thus, the fluorination plots may be reporting
on small differences in the binding distance and geometry between the ammonium center
and aromatic face of the indole ring.
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Figure 2.6.  Electrophysiological analysis of 5-HT analogs.  (a) N-Me-5-HT dose-
response relations and fits to the Hill equation for 5-HT3AR suppressed with Trp
(circles), F–Trp (squares), F2-Trp (diamonds), and F3-Trp (triangles) at position 183.
(b) 5-HTQ dose-response relations and fits to the Hill equation for 5-HT3AR
suppressed with Trp (circles), F–Trp (squares), F2-Trp (diamonds), and F3-Trp
(triangles) at position 183 (c) Fluorination plot for 5-HT (circles) and N-Me-5-HT
(squares) and 5-HTQ (triangles).
2.1.5 Effect of agonist alkylation state at the nAChR
As a complement to the studies of N-Me-5-HT and 5-HTQ at the 5-HT3AR,
Gabriel Brandt studied the behavior of the tertiary ACh analog, 2-dimethylaminoethyl
acetate (noracetylcholine, or norACh) and the "simplified" quaternary ACh analog,
tetramethylammonium (TMA) at the nAChR (Figure 2.4a).  While TMA is a very low-
potency agonist (Table 2.2), it does appear to experience a cation-? interaction with Trp
?149 similar to that seen for ACh (Figure 2.7).  Only data up to F3-Trp are available
because, as with other agonists studied, channel blockade by the agonist becomes a
serious problem at the high concentrations necessary to activate the receptor with F4-Trp
at ?149.  However, it is clear that progressive fluorination leads to a steady increase in
EC50 as seen with ACh.
The results for norACh highlight a significant difference between the 5-HT3AR
and the nAChR.  While substantial variation in the alkylation state of 5-HT has no
28
significant effect on potency, simply removing one methyl group from the quaternary
ammonium of ACh to produce norACh leads to vastly inferior potency.  The EC50 for
norACh is comparable to that of TMA.  The fluorination data for norACh are not
completely straightforward (Table 2.2).  While monofluorination shows a 7-fold
increase— comparable to ACh— di- and trifluorination show only modest increases and
tetrafluorination leads to a decrease in EC50 (Figure 2.7).
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Figure 2.7.   Fluorination plot for ACh (circles) and norACh (squares) and TMA
(triangles).
2.1.6 Nicotine dose-response to Fn-Trp series at ?149 in muscle nAChR
Nicotine is, of course, an important agonist of the nAChR, and all pharmacophore
models for this drug and related compounds align the protonated pyrrolidine nitrogen
with the quaternary ammonium of ACh.25-29  To evaluate this model, we studied nicotine's
potency with the series of fluorinated Trp derivatives at position ?149 of the nAChR.
The results are shown in Table 2.2 and Figure 2.8.  Dose-response relations were
collected for receptors with one (? subunit) or two (?? subunits) L9'S mutations.  The
data for ?L9'S receptors comes from Wenge Zhong, and Gabriel Brandt collected the
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??L9'S data.  The results are similar in each case.  If a single fluorine is added to the
tryptophan ring by incorporating F-Trp at position ?149, the EC50 increases almost three-
fold, which is comparable to the four-fold increase observed with ACh.  However, further
fluorination does not lead to a significant further increase in EC50.  Figure 2.8c shows a
fluorination plot for nAChR with a single L9'S mutation in the ? subunit.  Clearly, the
progressive rise in EC50 seen with ACh and other agonists is not seen with nicotine.
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Figure 2.8.   Electrophysiological analysis of nicotine and N-Me-nicotinium.  (a)
Nicotine dose-response relations and fits to the Hill equation for nAChR
suppressed with Trp (circles), F–Trp (squares), F2-Trp (diamonds), and F3-Trp
(triangles) at position 183.   (b) N-Me-nicotinium dose-response relations and fits to
the Hill equation for nAChR suppressed with Trp (circles), F–Trp (squares), F2-Trp
(diamonds), and F3-Trp (triangles) at position 183 (c) Fluorination plot for ACh
(circles) and nicotine (squares) and N-Me-nicotinium (triangles).
2.1.7 Nicotine dose-response to Trp analogs at ?55/?57 in muscle nAChR
The lack of a strong response to fluorination at Trp ?149 by nicotine indicates
that it does not experience a significant cation-? interaction with this residue.  This
suggests the possibility that another aromatic residue in the binding site might form a
cation-? interaction with nicotine.  Based on the crystal structure of AChBP, an appealing
candidate is Trp ?55/?57, which is adjacent to Trp ?149 in the binding site.  We therefore
evaluated the ?55/?57 pair using, instead of fluorination, the alternative comparison of
5-CN-Trp vs. 5-Br-Trp.   This nearly isosteric pair provides a useful qualitative indicator
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of a cation-? interaction, since the cyano group is much more strongly deactivating than
the bromo (Figure 2.3c).  For example, at ?149 with ACh as the agonist, the ratio of EC50
values for 5-CN-Trp/5-Br-Trp is 57.8  As shown in Table 2.2, the ratio, 5-CN-Trp/5-Br-
Trp is approximately 0.5 for nicotine at the ?55/?57 position.  This is not at all consistent
with a cation-? interaction between nicotine and this tryptophan.
2.1.8 N-methyl-nicotinium dose-response to Fn-Trp series at nAChR ?149
Both ACh and TMA show a progressive increase in EC50 with fluorination while
nicotine does not.  This suggests that a quaternary ammonium ion may be essential to see
this effect in nAChR binding.  To test this possibility, Gabriel Brandt evaluated the
quaternary analog, N-methyl-nicotinium in the ?? L9’S nAChR. As shown in Table 2.2,
the EC50 for N-methyl-nicotinium at wild-type receptors is similar to that of nicotine.  In
addition, N-methyl-nicotinium behaves quite similarly to nicotine in the fluorination plot.
Thus, the unusual behavior of nicotine is not due to the lack of a quaternary ammonium
group (Figure 2.8).
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Table 2.2.  Dose-response data for nAChR and unnatural amino acids
Residue EC50±SEM (µM) Hill±SEM
W149
Acha Trp 1.2 ± 0.0 NDb
? L9'S F-Trp 4.7 ± 0.1 ND
F2-Trp 13  ± 1 ND
F3-Trp 34  ± 1 ND
F4-Trp 65  ± 3 ND
TMA Trp 48   ± 2 ND
?,? L9'S F-Trp 155 ± 4 ND
F2-Trp 313 ± 8 ND
F3-Trp 789 ± 23 ND
norACh Trp 23   ± 6 2.62 ± 1.00
?,? L9'S F-Trp 161 ± 9 1.92 ± 0.26
F2-Trp 225 ± 28 1.62 ± 0.04
F3-Trp 327 ± 18 1.62 ± 0.03
F4-Trp 152 ± 4 1.53 ± 0.03
Nicotine Trp 45   ± 1 ND
? L9'S F-Trp 130 ± 5 ND
F2-Trp 172 ± 6 ND
F3-Trp 188 ± 11 ND
F4-Trp 136 ± 5 ND
Nicotine Trp 1.3 ± 0.3 2.92 ± 1.47
?,? L9'S F-Trp 4.2 ± 0.7 1.57 ± 0.09
F2-Trp 5.4 ± 0.5 1.53 ± 0.08
F3-Trp 12  ± 1 1.13 ± 0.07
F4-Trp 11  ± 1 1.28 ± 0.07
MeNicotinium Trp 0.8 ± 0.1 1.34 ± 0.07
?,? L9'S F-Trp 4.2 ± 0.4 1.44 ± 0.08
F2-Trp 5.7 ± 0.7 1.42 ± 0.09
F3-Trp 3.3 ± 0.4 1.33 ± 0.07
F4-Trp 4.6 ± 1.0 1.05 ± 0.13
W?55/?57
Nico CN-Trp 1.4 ± 0.2 ND
?2 L9'S Br-Trp 3.0 ± 0.4 ND
a  data from reference #7, Zhong et al. ,PNAS 1998, 95, 12088.
b  ND = no data
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2.1.9 Studies of agonist efficacy
The EC50 for a receptor is a composite measurement comprising multiple
elementary steps.  Even in the simplest two-state model of channel opening, agonist
binding to the closed channel is followed by a conformational change to an open channel
state.  Since the dose-response measurement does not distinguish between these two
steps, experiments were undertaken to determine whether binding or channel gating
accounted for the observed alterations in EC50 in response to increasing Trp fluorination.
The efficacy of a compound on a ligand-gated ion channel is reflected in the maximal
current passed at saturating agonist concentration under given electrophysiological
conditions.17, 30  Relative efficacies of all drugs were determined in ND96 medium in
oocytes clamped at a membrane potential of -80 mV at a concentration five times the
EC50 of the compound, and were determined for the various agonists at ?149 suppressed
receptors in nAChR and 183 suppressed receptors in 5-HT3AR.  The relative efficacy of
each agonist was calculated as the ratio of Imax for the agonist to Imax for ACh or 5-HT.
For the 5-HT3R and nAChR agonists considered here, there were no large
statistical differences in efficacy among them (Table 2.3), nor was the relative efficacy
ever observed to differ in receptors containing fluorinated Trp analogs.  The process of
channel gating is a complicated one and is postulated to involve numerous elementary
steps for the nAChR.  Thus, it is overly simplistic to conclude from these efficacy
experiments that the effects observed are due exclusively to binding.31  However, the fact
that all compounds tested exhibit similar ability to initiate the conformational changes
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associated with channel opening suggests the large effects that we see on potency most
likely arise from effects on agonist binding.
Table 2.3 Efficacy values for the 5???3?R and nAChR agonists
Residue Efficacy±SEM (%)a
nAChR W149
norACh Trp 81.8 ± 6.1
?,? L9'S F-Trp 96.0 ± 3.3
F2-Trp 69.2 ± 31
F3-Trp 40.4 ± 11
TMA Trp 97.5 ± 5.1
?,? L9'S F-Trp 62.1 ± 38
F2-Trp 94.4 ± 4.7
F3-Trp 95.2 ± 3.3
Nicotine Trp 88.9 ± 7.5
?,? L9'S F-Trp 81.8 ± 11
F2-Trp 82.8 ± 12
F3-Trp 67.7 ± 13
MeNicotinium Trp 86.4 ± 7.5
?,? L9'S F-Trp 83.8 ± 9.8
F2-Trp 87.9 ± 2.8
F3-Trp 79.3 ± 11
5-HT3AR W183
N-Me-5-HT Trp 70.7 ± 1.6
F-Trp 78.5 ± 3.3
F2-Trp 70.3 ± 2.5
F3-Trp 71.8 ± 3.4
5-HTQ Trp 75.0 ± 1.7
F-Trp 70.0 ± 7.1
F2-Trp 70.3 ± 11
F3-Trp 91.8 ± 4.3
a  efficacy is reported as the relative percentage of Imax for a given agonist to
Imax of ACh or 5-HT
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2.3 Discussion
The agonist response of a ligand-gated ion channel testifies to the organizing
power of weak, non-covalent interactions.  As the neurotransmitter approaches the much
larger receptor, it must not be lured in by sites whose charge, shape, and hydrophobicity
resemble the intended binding site.  Instead, the molecule diffuses within the synaptic
cleft and is drawn exactly to the appropriate location to trigger channel opening.  In the
case of the nicotinic acetylcholine receptor, we have previously proposed a unique role
for Trp149 in the ? subunit in the binding of the natural agonist, acetylcholine.8  Based
on subtle alterations of the electrostatic surface of the side chain at this position, it was
concluded that this site participates in a strong cation-? interaction with the quaternary
ammonium center of ACh.  More recent structural work from other labs on AChBP has
confirmed this conclusion.2  The work presented here extends this technique to the
serotonin receptor, 5-HT3AR.  In addition, the experimental scope is expanded at both the
nAChR and 5-HT3AR to consider in greater detail the nature of the interaction between
agonist and receptor.  Homology between the 5-HT3AR, the alpha subunit of the muscle
nAChR, and AChBP is significant, with strong conservation of the tryptophan residues
making up two sides of the ligand-binding site box.  In addition, two of the three tyrosine
residues seen in the nAChR and AChBP are aromatic amino acids in 5-HT3AR (Figure
2.2).32
The introduction of a series of fluorinated Trp analogs at position 183 of the
mouse 5-HT3AR provides clear evidence for a cation-? interaction between this residue
and serotonin, as suggested by earlier site-directed mutagenesis studies.33  This
interaction appears to be unique to Trp183.  Substitution of the fluorinated Trp series at
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Trp 90— also in the binding site region— causes no significant effects.  We thus
conclude that both the nAChR and the 5-HT3AR make use of a single potent cation-?
interaction in recognizing the ammonium centers of their respective agonists.
Interestingly, the slope of the plot relating EC50 to calculated cation-? binding
energy (the fluorination plot) is visibly different for ACh binding to nAChR than
serotonin binding to the 5-HT3AR.  Inspection of Figure 2.5c shows that the serotonin
slope is markedly steeper.  We interpret this to mean that the strength of the cation-?
interaction between the agonist and the relevant tryptophan is greater when serotonin is
the agonist than when ACh is the agonist.  This result is consistent with expectations
based on electrostatics.34  As shown in Figure 2.4, the smaller, primary ammonium center
of serotonin presents a more focused positive charge than the quaternary center of ACh.
Given the strong electrostatic component of the cation-? interaction, smaller ions are
expected to show a stronger interaction.
The data for ACh and serotonin also provide one way to address a long-standing
issue in molecular recognition: what is the strength of a cation-? interaction?  From
Figure 2.3a, it may be observed that the surface of F4-Trp is essentially electrostatically
neutral.  Thus, a comparison of F4-Trp and Trp provides a measure of the electrostatic
component of the cation-? interaction.  The F4-Trp/Trp ratio reflects the energy cost of
removing the attractive electrostatics, but maintaining the residue as if the Trp were
replaced by a hydrophobic residue of the same shape.  This new residue maintains most
van der Waals and dispersion interactions, but cannot experience a cation-? interaction.
For ACh, the F4-Trp/Trp ratio is 54.  For serotonin, the F4-Trp EC50 value is obtained by
extrapolation of the line in Figure 2.5c which leads to a F4-Trp/Trp ratio of 836.  If these
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are viewed as ratios of binding constants, then the implied energetics of a cation-?
interaction are 2.4 kcal/mol and 4.0 kcal/mol, respectively for ACh and serotonin.  These
are consistent with other estimates of the magnitude of the cation-? interaction,7 and
further establish that this non-covalent binding force is comparable to, or stronger than,
any other individual force considered in biological recognition.
In an effort to probe the molecular recognition properties of these receptors
further, we studied the effects of varying the alkylation state of the cationic center of the
agonist.  In such studies, a clear distinction emerges between the 5-HT3AR and the
nAChR.  At the serotonin receptor, the monoalkylated agonist, N-Me-5-HT and the
quaternary agonist, 5-HTQ show essentially the same EC50 as the natural agonist 5-HT.
This suggests that the 5-HT3AR agonist binding site is fairly tolerant, accommodating the
much bulkier 5-HTQ with no loss in potency.  These two unnatural agonists respond to
fluorination much like the natural agonist, serotonin, although the perfect linear trend of
Figure 2.5c is not reproduced.  We hesitate to provide an extensive interpretation of this
subtle distinction in which multiple variables, including both the agonist and the protein,
are being changed.  However, it is clear that a strong cation-? interaction to Trp 183 is
involved with all of these agonists.
The nAChR behaves quite differently from the 5-HT3AR in this regard.  First, the
change from ACh to norACh leads to a very large increase in EC50.  Simply removing
one methyl group from ACh produces a very low-potency agonist.  In fact, norACh is
comparable in potency to tetramethylammonium (TMA), which lacks several moieties of
the ACh molecule.  Interestingly, the quaternary TMA— although a very low-potency
agonist— does show a fluorination trend that is similar to that of ACh (Figure 2.7).  The
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norACh fluorination trend is less well-behaved with a large increase for F-Trp, followed
by minimal further effects for F2-Trp and F3-Trp, which are then followed by a downturn
at F4-Trp (Figure 2.7).  While this suggests some kind of cation-? interaction for the
norACh agonist, more subtle factors may also be operative for this low-potency, non-
native agonist.  Clearly, the nAChR is much more sensitive to alterations in the region of
Trp ?149 than the 5-HT3AR is to comparable changes with the aligned Trp 183.
This leaves the case of nicotine— an obviously important agonist of the nAChR.
Before discussing the results, a few general comments are in order.  The receptor studied
here is the muscle-type receptor— the isoform found at the neuromuscular junction in the
peripheral nervous system.  Nicotine is a full agonist at this receptor, but as shown in
Table 2.2, nicotine is not an especially potent agonist at the muscle receptor.  The
behavioral and addictive effects of nicotine arise exclusively from effects on the neuronal
nAChRs.35-38  These receptors are expressed widely in the central nervous system.39, 40
While the overall architecture of neuronal nAChR is no doubt the same as the muscle
type described here, the neuronal receptors are comprised of different combinations of ?
and ? (non-?) subunits.  There are many variants of each subunit, but they are highly
homologous to the muscle subunits, and all the residues discussed here are conserved in
the neuronal receptors.  At present, at least 10 ? and 4 ? forms are known, termed ?1-10
and ?1-4 (?1 and ?1 are the muscle forms; all the rest are neuronal).  Nicotine addiction is
thought to depend partially on receptors formed from ?4 and ?2 subunits (stoichiometry
unknown) and perhaps receptors involving ?7.37, 38, 41, 42  While we believe our findings are
clearly relevant to the pharmacology of nicotine, it must be remembered that subtle
variations could arise in comparable studies of the neuronal receptors.
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The fluorination plot for nicotine is shown in Figure 2.8b.  In light of our findings
for ACh versus norACh, we also studied N-Me-nicotinium in which the pyrrolidine
nitrogen has been quaternarized.  Interestingly, these two nicotinoid agonists are similar,
both in potency and in their fluorination plots.  The nicotine fluorination plot has the
shallowest slope of any agonist examined at either the nAChR or the 5-HT3AR.  After a
relatively small jump in EC50 for F-Trp, only very small changes in EC50 are seen upon
further fluorination of Trp ?149.  This is strong evidence that nicotine does not make a
strong cation-? interaction with Trp ?149 of the muscle-type nAChR.
One possibility is that nicotine makes a cation-? interaction with one of the other
aromatics that form the “aromatic box” of the nAChR binding site.  A sensible candidate
is ?55/?57— the other conserved Trp in the agonist binding site.  This residue has been
implicated in nicotine binding by photoaffinity labeling studies from the Cohen group.43,
44  As a probe of this site, we studied the pair 5-CN-Trp/5-Br-Trp.  It has been previously
shown that this nearly isosteric pair can provide a good qualitative indication of a cation-
? interaction, since the cyano group is much more strongly deactivating than the bromo.
The pair differ by a factor of 57 for ACh at Trp ?149.8  However, no significant effect is
seen at ?55/?57 with nicotine (or ACh) as the agonist, ruling out this site for a cation-?
interaction with nicotine at the muscle receptor.
Subsequent to the completion of this work, several studies examining the
anomalous binding properties of nicotine were reported.  Taken together, these studies
provide a more detailed portrait of nicotine binding to the nAChR.  Modeling studies
based on the structure of AChBP suggested a hydrogen bonding interaction from the
N+–H of nicotine to the backbone carbonyl of Trp ?149.45, 46  Amanda Cashin and E.
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James Petersson, in a study combining both functional data from backbone ester
mutations at Thr ?150 and computational work, demonstrated that nicotine binding
depends on a hydrogen bond with the backbone carbonyl of ?149.47  More recently
Sixma and co-workers reported the crystal structure of AChBP in the presence of bound
nicotine.5  This structure verified that nicotine does not form a cation-? interaction with
Trp ?149, and that bound nicotine does indeed make a hydrogen bond with the backbone
carbonyl of ?149.
The conclusion that nicotine does not bind to the muscle nAChR via a cation-?
interaction with tryptophan residues in the aromatic box has implications for existing
pharmacophore models of the nAChR.  All current pharmacophore models align the
quaternary ammonium of ACh with the protonated tertiary amine of nicotine.25-29  It
seems an unavoidable conclusion that such a model requires a cation-? interaction
between the cationic center of nicotine and Trp ?149, but it is now clear that, at least in
the muscle nAChR, such a cation-? interaction does not exist.  The data with norACh
suggest that the nAChR is quite sensitive to variations in agonist structure at the cationic
center— much more so than the 5-HT3AR.  As nicotine analogs are assuming a greater
prominence for drug leads in a variety of important diseases, some caution in applying
the standard pharmacophore model seems to be in order.
2.4 Conclusions
Earlier work in the Dougherty group demonstrated that the nonsense suppression
methodology provides a powerful tool for evaluating drug-receptor interactions.  In
particular, fluorination plots can clearly identify a specific cation-? interaction between
an agonist and its receptor.  Here, we build upon those findings in several ways.
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A clear cation-? interaction between serotonin and Trp 183 of the 5-HT3AR is
established.  A measure of the magnitude of the electrostatic component of the cation-?
interaction is provided.  We find it to be worth ~2 kcal/mol for ACh at the nAChR and ~4
kcal/mol for serotonin at the 5-HT3AR.  Studies of other agonists highlight the differences
between the two homologous receptors: the nAChR and the 5-HT3AR.  The latter is
relatively tolerant of changes at the cationic center and maintains a cation-? interaction,
while the nAChR seems quite sensitive to changes in the nature of the cationic center of
the agonist.  Finally, studies of the binding of nicotine to the muscle nAChR suggest that
present pharmacophore models require revision.  Work on the neuronal nAChR will be
required to further explore this issue.
2.5 Methods
2.5.1 Electrophysiology
Stage VI oocytes of Xenopus laevis were harvested according to approved
procedures.  Recordings were made 24 to 72 hours post-injection in standard two-
electrode voltage clamp mode.  Oocytes were superfused with calcium-free ND96
solution, as previously reported8.  Nicotinic agonists were either synthesized as described
earlier (N-methyl-nicotinium)48, or purchased from Sigma/Adrich/RBI ([-]-nicotine
tartrate) or Acros Organics (the tertiary ACh analog, 2-dimethyl aminoethyl acetate).
Serotonin and its analogs were purchased from Sigma/Adrich/RBI.  All drugs were
prepared in sterile ddi water for dilution into calcium-free ND96.  Dose-response data
were obtained for a minimum of eight concentrations of agonists for a minimum of three
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different cells.  Curves were fit to the Hill equation to determine EC50 and Hill
coefficient.
2.5.2 Unnatural amino acid suppression
Synthetic amino acids were conjugated to the dinucleotide dCA and ligated to
truncated 74 nt tRNA as described.9  Deprotection of charged tRNA was carried out by
photolysis immediately prior to co-injection with mRNA in the manner described.8, 49
Typically, 25 ng tRNA were injected per oocyte along with mRNA in a total volume of
50 nL per cell.  mRNA was prepared by in vitro runoff transcription using the Ambion
mMagic mMessage kit.  Mutation to insert the amber stop codon at the site of interest
was carried out by standard means and was verified by sequencing through both strands.
For nAChR suppression, a total of 4.0 ng of mRNA was injected in the subunit ratio of
10:1:1:1 ?:?:?:?.  In many cases, one or more subunits contained a L9’S mutation, as
discussed above.  As reported previously, mouse muscle embryonic nAChR in the pAMV
vector was used.  For suppression in homomeric 5-HT3AR, 5.0 ng of mRNA was injected.
Mouse 5-HT3AR was used in all cases, in the pAMV vector. Negative and positive
controls for suppression were performed in the following way: as a negative control,
truncated 74 nt tRNA or truncated tRNA ligated to dCA was co-injected with mRNA in
the same manner as fully charged tRNA.  At the positions studied here, no current was
ever observed from these negative controls.  The positive control involved wild-type
recovery by co-injection with 74 nt tRNA ligated to dCA-Trp.  In all cases, the dose-
response was indistinguishable from injection of wild-type mRNA alone.
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Chapter 3. Structure-function studies of tyrosines in the ligand-binding
pocket of the 5-HT3R
3.1 Introduction
The determination of the structure of the ACh binding protein (AChBP) which is
homologous to the extracellular domain of the nACh receptor (nAChR) has had a
significant impact on the study of ligand-gated ion channels (LGIC).1  As the first high-
resolution portrait of the extracellular domain of these proteins, it has provided crucial
structural information for structure-function studies.  In addition, lower resolution images
from cryo-electron microscopy (cryo-EM) have contributed to our understanding of the
global structure of these receptors.2-6  Insights from both the AChBP and cryo-EM
structures have led to a model of channel opening in which agonist binding induces a
rotation of the extracellular domains.  This is then thought to be transduced via the
M2–M3 loop to M2, the pore-lining domain.  The subsequent rotation of M2 removes the
hydrophobic residues lining the channel and allows the passage of ions.2  Although this is
a plausible model, more experimental data are required both to substantiate it and to
determine the molecular details of these processes.
One area where the AChBP structure has proven particularly valuable is in the
generation of homology-based models.  Homology models based on AChBP have been
constructed for the nACh, GABAA, and 5-HT3 receptors.
7-10  The homology model of the
5-HT3R reveals a ligand-binding pocket containing a large proportion of aromatic
residues.8  Two of these residues are tryptophans, one of which (Trp 183) forms a
cation-? interaction with agonist.11  There is also a phenylalanine (Phe 226), but most of
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the aromatic character is provided by tyrosines (Tyr?141, Tyr 143, Tyr 153, and Tyr 234).
The agonist-binding site in LGICs is composed of several non-contiguous loops (loops
A-E).  Tyrosines 141, 143, and 153 are located in loop E which is contributed to the
binding site by the minus-side subunit (or in nAChR terms, the non-alpha subunit). This
loop is not highly conserved in other members of the Cys-loop LGIC family.  Tyr 234 is
in loop C which is contributed by the plus-side subunit (or alpha-subunit in nAChR), and
is universally conserved in the Cys-loop superfamily.  Previous data have shown the
importance of these residues in the binding and/or function of the 5-HT3R, but it has not
been possible to define their exact roles.12, 13
The work presented in this chapter combines conventional mutagenesis and
nonsense suppression methodology to examine the functional roles of these binding-site
tyrosines in the 5-HT3R.  This work represents a collaboration with the Sarah Lummis
group of Cambridge University, and in particular Kerry Price, who performed all of the
conventional mutagenesis experiments and binding studies.  In addition she supplied
significant contributions and effort to the nonsense suppression studies.  It should also be
noted that all of the modeling work considered here was generated by our Cambridge
colleagues.
Using nonsense suppression, a series of tyrosine analogs was introduced at each
tyrosine site (Figure 3.1).14, 15  The tyrosine analogs were selected based on rational
perturbations of tyrosine’s physico-chemical properties.  The precision afforded by
unnatural amino acids provided key information for delineating the functional role of
these tyrosines.  Assimilating these data with the homology model of the 5-HT3R binding
site into which 5-HT has been computationally docked allowed us to confirm the
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orientation of 5-HT in the agonist binding pocket and to determine several non-covalent
interactions that are important for receptor binding and/or gating.  This information was
used to generate a possible mechanism by which agonist binding could trigger a series of
conformational changes near the binding site that may initiate the gating process.
OH F Br CH3 OCH3
OH OH F F
F F FF
FFHOHO
Tyr Phe 4-F-Phe 4-Br-Phe 4-Me-Phe 4-MeO-Phe
L-DOPA mTyr hTyr F3Phe F5Phe Cha
Figure 3.1. Structures of the side chains incorporated by nonsense suppression
3.2 Results
3.2.1 Nonsense suppression control experiments
3.2.1.1 Rescue of wild type through reintroduction of tyrosine
As an initial test of the viability of nonsense suppression at these sites, tyrosine
was incorporated via acylated tRNA at each of the four positions (141, 143, 153, and
234).  For the nonsense suppression methodology to give reliable results, the EC50 values
and Hill coefficients for activation by 5-HT must replicate those of the wild-type (non-
suppressed) 5-HT3AR, heterologously expressed in Xenopus oocytes.
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All mutant mRNAs, when co-injected into Xenopus oocytes with tRNA-Tyr, produced
functional receptors that responded to application of 5-HT with an inward current that
desensitized in response to maintained 5-HT.  The results shown in Tables 3.1 and 3.2
establish that the EC50 values and Hill coefficients obtained from 141-Tyr, 143-Tyr, 153-
Tyr, and 234-Tyr and wild type receptors were indeed similar to each other. This
indicates that the wild-type phenotype was successfully “rescued” by the delivery of
tRNA-Tyr molecules.
3.2.1.2 Validation of the pGEMHE vector
One novel feature of these studies was the use of the pGEMHE vector.16
Traditionally we have almost exclusively relied on the pAMV vector for nonsense
suppression.  This vector produces reliable expression and results, but is not the most
amenable vector for subcloning, in that the start codon of the open-reading frame must be
placed adjacent to the AMV sequence.  This requirement limits the possible restriction
enzymes for subcloning.  The pGEMHE vector is a high expression oocyte vector and
does not have such stringent subcloning requirements.
Suppression experiments using pGEMHE showed that maximal 5-HT-induced
currents (Imax) were typically 0.8–2 µA at a holding potential of -60mV (Figure 3.2).  This
suggests that the pGEMHE vector can yield levels of full-length, correctly folded protein
at least as high as the original pAMV vector.15  The efficiency of nonsense suppression
has been estimated at ~10 percent14, and comparison of Imax values for the wild-type
5-HT3A receptor expressed in oocytes using pGEMHE to rescued TAG mutant receptors
suggests a similar efficiency here.
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Figure 3.2.   (a) Representative voltage-clamp current traces for oocytes expressing
suppressed 5-HT3AR. Bars represent application of 5-HT.  (b) Representaive
maximal currents (Imax) for suppression experiments using the pGEMHE vector,
obtained from 5-HT3AR suppressed at postion 234.
3.1.1.3 Testing read-through
No currents in response to application of high concentrations of 5-HT (1mM)
were detected from oocytes injected with mRNA alone or with mRNA and tRNA not
ligated to dCA-aa (THG73 74-mer tRNA).  It therefore appears that transcripts, which
have been truncated by the inclusion of a stop codon at the position of the mutated
tyrosine residue, cannot produce functional receptors.  This is to be expected because
these truncated receptors would contain none of the transmembrane regions required for
ion channel activity.  We can also conclude that any amino acid that is incorporated into
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these four sites of the mutant receptor is specifically introduced by the injected tRNA-aa
and not by the endogenous tRNA population of the oocyte.  Finally, the lack of response
from oocytes injected with mRNA and unacylated tRNA shows that there is no detectable
reacylation of tRNA by endogenous synthetases.
3.1.2 Incorporation of unnatural amino acids
A subset of the unnatural amino acids shown in Figure 1 was selected for testing
at each of the mutant positions.  These compounds were previously incorporated into the
nAChR and are therefore compatible with the oocyte expression system.14, 15  In addition
to the standard amino acids tyrosine and phenylalanine, the amino acids tested include:
3-hydroxyphenylalanine (meta-tyrosine or mTyr), homotyrosine (hTyr), L-DOPA,
4-methylphenylalanine (4-Me-Phe), 4-fluoro-phenylalanine (4-F-Phe),
2,4,6-F3-phenylalanine (F3-Phe), 2,3,4,5,6-F5-phenylalanine (F5-Phe),
4-methoxyphenylalanine (4-MeO-Phe), and cyclohexylalanine (Cha).
Current traces from a typical dose-response experiment (4-F-Phe at position 234)
are shown in Figure 3.2.  Although there were changes in the EC50 values and Hill
coefficients for some mutant receptors (see below), activation and desensitization kinetics
were similar to wild type for all receptors incorporating unnatural amino acids that
responded to 5-HT.
3.1.3 Tyr 141
Incorporation of Phe, mTyr, 4-F-Phe, 4-MeO-Phe, F5-Phe, and Cha using
nonsense suppression mutagenesis and substitution by the natural amino acids Ala, Ser,
and Phe using standard mutagenesis techniques produced receptors that responded to
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5-HT in a manner very similar to wild-type 5-HT3AR (Figure 3.3, Table 3.1 and Table
3.3).  These data therefore show that neither the aromatic nor the hydroxyl groups are
important for agonist binding or receptor gating.  However, this residue has been
implicated in antagonist binding because changes in affinity of 5-HT3 R antagonists have
been observed when this residue was substituted with a non-aromatic amino acid.12, 13
Thus, Tyr141Ala receptors have decreased [3H]granisetron, D-tubocurarine, and lerisetron
binding affinity compared with wild-type receptors, whereas Tyr141Ser receptors do not
bind [3H]granisetron at all.  The model of the 5-HT3R binding site (Figure 3.5) [based on
model 4 of reference #8] supports these data, because Tyr 141 could contact these larger
antagonists, but is not close enough to be in direct contact with a bound 5-HT molecule.8
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Figure 3.3.  Dose-response relations for 5-HT3AR nonsense suppression
experiments.  (a) Suppression at position 141: Tyr (open circles), mTyr (filled circles),
4-Me-Phe (filled squares), Phe (filled triangles), 4-F-Phe (open triangles), F5Phe (open
squares), and Cha (filled diamonds).  (b) Suppression at position 143: Tyr (open circles),
hTyr (open triangles), and DOPA (open squares).
In previous studies, Tyr141Ala and Tyr141Ser receptors did not function when
expressed in human embryonic kidney 293 cells.12, 13  However, our data show they have
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similar characteristics to wild-type receptors when expressed in oocytes.  Oocytes are
generally more tolerant than mammalian cells to expression of ion channel proteins,
which may require longer periods to fold correctly, the difference perhaps arising from
the fact that oocytes are incubated at lower temperatures which would favor complex
multisubunit assemblies.17  These data therefore suggest a role for this residue in correct
receptor folding and/or assembly, perhaps locally in the binding-site region.
3.1.4 Tyr 143
Data from Tyr 143 mutant receptors suggest that an aromatic ring with a hydroxyl
group at the 4 position is essential for efficient receptor function.  DOPA, which has
these groups, was the only substitution at 143 that produced receptors with less than a
10-fold increase in EC50.  Incorporation of even subtle changes such as 4-F-Phe,
4-MeO-Phe, and mTyr resulted in receptors that did not respond to 5-HT (Table 3.1).
DOPA also has a hydroxyl at the 3 position, and the increase in EC50 observed with this
compound (approximately sixfold) suggests that bulk here is not desirable.  An increased
chain length or removal of the hydroxyl, however, is more deleterious.  Phe and hTyr
caused 30- to 40-fold increases in EC50.  Removal of the aromatic group and/or further
displacement of the hydroxyl group as in replacement with Ala or Ser resulted in even
more severe changes: 100-fold EC50 increases.  In addition,  changes in apparent
activation and desensitization rates (10–90% rise times were twofold to fourfold slower
than wild-type receptors) (Table 3.3), and little or no desensitization were observed.
These data demonstrate the importance of both the aromatic and the hydroxyl group of
Tyr 143, and in particular, suggest that the hydroxyl forms a hydrogen bond that is
essential for efficient receptor gating.
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To confirm the presence of such a bond would require x-ray crystal structural data
which unfortunately, is not available.  However, mutagenesis data alone can provide
strong evidence, particularly when there is some supporting structural data such as a
homology model.18  Indeed, the unnatural amino acid methodology employed here is a
much more powerful probe for this type of bond than conventional mutagenesis because
not only can we introduce subtle changes that minimally perturb the global protein
structure, but also design the amino acid to determine whether the residue acts as a
hydrogen bond donor or acceptor.  Thus, using conventional mutagenesis, we can remove
the hydroxyl at position 143 (in Phe), but not replace it.  Ser is unsatisfactory as a
replacement because hydrogen bonds depend critically on the distance between donor
and acceptor atoms, and the hydroxyls of Ser and Tyr are in quite distinct locations.
Unnatural amino acid substitution can surmount this problem; DOPA has a similarly
placed hydroxyl to Tyr, whereas 4-MeO-Phe places an oxygen atom in the same location,
and the hydroxyl of hTyr is only subtly displaced from that of Tyr.  Data from these
substitutions support the proposal of a hydrogen bond at Tyr 143 and indeed, further
suggest that the hydroxyl here acts as a hydrogen bond donor.
The model of 5-HT docked into the 5-HT3AR extracellular domain (Figure 3.5)
shows that the hydroxyl of Tyr 143 has the potential to hydrogen bond with one of a
number of residues on the opposite side of the binding pocket.  These are the hydroxyl or
the ring of Tyr 234 and the carbonyl oxygen of Trp 183 or Leu 184, all of which are 3Å
away.  The fact that 4-Me-Phe could substitute satisfactorily for Tyr 234 suggests that
there is no such bond between the hydroxyls of Tyr 143 and Tyr 234, but as yet, we
cannot exclude any of the other possibilities.  Of course, the accuracy of the inter-residue
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distances must be viewed with caution both because of the problems inherent with using
a model based on a homologous structure, and because in the docking procedure, the
protein side chains remain rigid, which is certainly not the case in the functioning
receptor.  Nevertheless, the modeling data suggest that the most probable hydrogen
bonding partner of Tyr 143 is the backbone carbonyl of Trp 183— an interaction that has
also been previously suggested.19
The presence of either an aromatic or a hydroxyl at position 143, however, is not
essential for antagonist interactions: alanine, serine, and phenylalanine mutants of
Tyr?143 bound [3H]granisetron with an affinity similar to wild-type receptors (Table
3.3).12, 13  Competitive antagonists such as granisetron bind in the binding pocket, but
cannot trigger the conversion to the open state. These data, combined with the modeling
data, thus suggest that neither an aromatic group nor a hydrogen bond is required for
ligand binding, but both are essential for efficient receptor gating.
3.1.5 Tyr 153
Large increases in EC50 values, modifications in receptor kinetics, and changes in
[3H]granisetron binding affinity (Figure 3.4, Table 3.2 and Table 3.3) in mutant receptors
suggest that Tyr 153 plays a role in both binding and gating of the receptor.  The data
show that both an aromatic ring and a hydroxyl group in the 4 position are required for
correct receptor function. Removing (Ala, Ser) or drastically perturbing   (F5Phe)  the
aromatic ring resulted in 100-fold increases in EC50,.  Deleting the tyrosine hydroxyl
group (Phe) or replacing it (4-F-Phe or 4-Me-Phe) led to ~20-fold increases in EC50, and
relocating it (mTyr and Ser) resulted in 100-fold EC50 increases.  However, 4-MeO-Phe
increased EC50 only sixfold, indicating that the importance of the hydroxyl is via its
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oxygen atom.  These data strongly indicate the presence of a hydrogen bond with the
hydroxyl of Tyr153 functioning as a hydrogen bond acceptor.
Table 3.1 Dose-response data for suppression at positions 141 and 143
Residue 141 143
EC50±SEM (µM) Hill±SEM EC50±SEM (µM) Hill±SEM
Tyr 1.16 ± 0.04 2.76 ± 0.20 1.15 ± 0.03 2.98 ± 0.19
Phe 0.92 ± 0.06 2.80 ± 0.44 78.6 ± 2.86 2.73 ± 0.21
4-MeO-Phe 3.36 ± 0.14 2.17 ± 0.16 NR NR
4-F-Phe 1.32 ± 0.05 2.47 ± 0.17 NR NR
F5-Phe 1.38 ± 0.08 1.89 ± 0.17 NA NA
Cha 3.14 ± 0.40 1.92 ± 0.21 NA NA
mTyr 1.69 ± 0.06 3.24 ± 0.29 NR NR
hTyr NA NA 33.24 ± 2.60 1.80 ± 0.22
DOPA NA NA 7.16   ± 0.90 2.34 ± 0.54
NA = not attempted, NR = no response to concentrations up to 1 mM 5-HT
Table 3.2 Dose-response data for suppression at positions 153 and 234
Residue 153 234
EC50±SEM (µM) Hill±SEM EC50±SEM (µM) Hill±SEM
Tyr 1.15 ± 0.04 2.78 ± 0.20 1.24   ± 0.05 2.89 ± 0.28
Phe 22.5 ± 0.43 2.60 ± 0.11 10.22 ± 0.80 1.92 ± 0.26
4-MeO-Phe 6.65 ± 0.27 1.98 ± 0.12 NA NA
4-F-Phe 19.7 ± 1.22 1.82 ± 0.14 4.11 ± 0.20 2.36 ± 0.19
4-Br-Phe NA NA 1.78 ± 0.08 2.79 ± 0.32
4-Me-Phe 18.2 ± 0.48 2.48 ± 0.11 1.13 ± 0.05 2.49 ± 0.22
F3-Phe NA NA NR NR
F5-Phe (>500) NR NR
Cha NA NA NR NR
mTyr (>500) 7.42 ± 0.32 2.83 ± 0.32
NA = not attempted, NR = no response to concentrations up to 1 mM 5-HT
In the homology model, this hydroxyl is located such that it could participate in a
hydrogen bond interaction, either with the 5-HT indole nitrogen (2.9 Å away) or with Arg
92 (3.1 Å).  Arg 92— like Tyr 153— is located on the subunit “inner loop,” which is
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proposed to move relative to the “outer loop” after receptor activation.3  Because the
relative movement of the two residues during channel opening would therefore be
negligible, it is unlikely that removing a hydrogen bond here would result in the changes
that we observed.  It therefore seems plausible that Tyr 153 hydrogen bonds to 5-HT.
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Figure 3.4.  Dose-response relations for 5-HT3AR nonsense suppression
experiments.  (a) Suppression at position 153: Tyr (open circles), Phe (open squares),
4-F-Phe (open triangles), and 4-MeO-Phe (open diamonds).  (b) Suppression at position
234: Tyr (open circles), mTyr (open diamonds), Phe (open squares). 4-F-Phe (filled circles),
and 4-Me-Phe (open triangles).
3.1.6 Tyr 234
Replacement of tyrosine at this position with Phe, 4-F-Phe, mTyr, and 4-Me-Phe
produced receptors for which EC50 values for 5-HT activation were either unchanged or
increased only 10-fold compared with wild-type receptors (Figure 3.4, Table 3.2).  Thus,
the hydroxyl group of Tyr 234 is not essential for correct receptor function.  Indeed, the
equivalent residue here in the guinea pig 5-HT3R is Phe.
20  The electrostatic potential of
the aromatic group here, however, does seem important.  Replacement with Cha, Ala or
Ser resulted in nonfunctional receptors.  In many ways Cha is an ideal mutation for
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examining the importance of aromatic character.  It is nearly isosteric with Phe and
maintains very similar shape and hydrophobicity, but cannot participate in any of the
special aromatic interactions (cation-?, CH-?, or aromatic-aromatic).  Thus, its non-
viability at this site does suggest a role for the aromatic character of Tyr.
The potential importance of the aromatic group is supported by the results with
4-F-Phe and F5-Phe.  Here, a single fluorine substituent (4-F-Phe) caused a small increase
in EC50, and multiple fluorine substituents (F5-Phe ) resulted in nonfunctional receptors.
Substitution of the aromatic group with electron-withdrawing groups pulls electron
density away from the face of the aromatic ring, thereby disrupting the special aromatic
interactions listed above.  The data, however, are not consistent with a cation-?
interaction at 234.  Phe— which displays a similar affinity as Tyr in binding cations—
leads to an eightfold increase in EC50, but 4-F-Phe and 4-Br-Phe— both of which would
almost equally weaken any cation-? interaction, lead to roughly 1.5- and 3-fold increases,
respectively in EC50.  These results are not consistent with a cation-? interaction at 234,
which is interesting because in the model (Figure 3.5), this residue has the potential to
interact with the primary ammonium of 5-HT.  Thus, these results provide experimental
feedback for improving the homology model.
The pattern of EC50 values for unnatural amino acid substitution at 234 is
consistent with bulk at the 4 position of the aromatic ring being required for correct
receptor function.  Those residues with a substituent at the 4 position (4-Me-Phe,
4-Br-Phe, and 4-F-Phe) give lower EC50 values than those without (Phe, mTyr).  Such a
finding was reported for the aligning residue ( Tyr198) in the nAChR21, where a larger
number of unnatural residues were tested.  The size of this substituent also appeared to be
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important, with larger substituents not being tolerated and smaller ones also being less
favored, suggesting a steric role.
Table 3.3 Conventional mutagenesis studies: dose-response data,
[3H]granisetron binding affinities, and 10-90% rise times for current onset
Residue EC50±SEM (µM) Hill±SEM Kd (nM) Rise time (s)
Wild type (Y) 1.34 ± 0.12 2.38 ± 0.23 0.32 ± 0.035 2.1 ± 0.3
141
Ala 2.73 ± 0.15 2.68 ± 0.4 8.97 ± 2.44 2.4 ± 0.2
Ser 4.7   ± 0.38 2.02 ± 0.31 NB 2.4 ± 0.3
Phe ND ND 0.98 ± 0.15 ND
143
Ala 354  ± 29.0 2.62 ± 0.53 1.2   ± 0.24 7.9 ± 0.5
Ser 472  ± 47.9 2.68 ± 0.62 1.1   ± 0.23 8.4 ± 0.8
Phe 78.6 ± 2.86 2.73 ± 0.21 0.53 ± 0.10 4.5 ±1.0
153
Ala 120  ± 9.43 2.43 ± 0.38 3.62 ± 1.75 8.3 ± 0.7
Ser 84.1 ± 5.60 2.54 ± 0.37 NB 8.1 ± 0.4
Phe ND ND 0.53 ± 0.10 ND
ND = No data, NB = No binding
3.1.7 A new model of the 5-HT binding pocket
The new data strongly support previous suggestions by the Lummis group arising
from their modeling studies that the correct orientation of 5-HT in the binding pocket is
with the ammonium group located between Trp 183 and Tyr 234.  In addition, the data
are consistent with hydrogen bonds between Tyr 143 and Trp 183, and Tyr 153 and 5-HT
(Figure 3.5).  The Lummis group also created a new “closed state” model based on the
structural work by Unwin and coworkers.3  Unwin’s data indicate differences in the
binding pocket between the closed state of the nAChR and AChBP (which is considered
to be closer to the open or desensitized state).  In the closed state model, Tyr 143 and 153
are 3?Å closer to the center of the pocket, and clashes between these residues and 5-HT
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indicate that binding of this agonist in the orientation supported by the experimental data
is not possible (Figure 3.6).  Antagonist binding, however, would not be affected.  Thus,
if we assume that similar movements in the binding pocket occur in the nACh and 5-HT3
receptors, and that the new model provides a reasonable approximation of the closed state
of the receptor, then Tyrs 143 and 153 would need to be displaced to allow 5-HT to dock
into the binding site (Figure 3.6).
3.3 Discussion
The in vivo nonsense suppression method of unnatural amino acid incorporation is
a powerful tool for the investigation of receptor structure-function relationships.  Using a
selection of tyrosine analogs, we show that tyrosines located in or close to the receptor
binding pocket each play a different role in receptor function and do not simply provide a
featureless extended aromatic environment.  Tyr 141 does not appear to be a critical site,
as the various mutations introduced here had little effect.  Tyr 143 and Tyr 153, however,
are important sites for receptor function, and the results for substitution at these sites
indicate that the hydroxyls of these tyrosines form functionally necessary hydrogen
bonds.  At Tyr 234 we find that both the aromatic group and an appropriately sized
substituent at the 4 position of the ring are important.  These data, combined with
previous work from the Dougherty group elucidating the cation-? interaction between
Trp 183 and the ammonium group of 5-HT11, have provided insight into the correct
orientation of 5-HT in a homology model of the 5-HT3R binding site.  In addition,
findings from the present study, along with a new closed state model of the 5-HT3R,
suggest a possible series of bond rearrangements in the binding site that are required for
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gating, and thus may represent early conformational changes that lead to channel
opening.
(a)
(b)
Figure 3.5.   Model showing two views of 5-HT docked into the 5-HT3A receptor
binding site.  This is based on model 4 of reference #8 (Reeves et al. (2003)).
Tyrosine residues considered here are shown in purple for loop E (141, 143, 153)
and orange for loop C (234,).  Docked 5-HT is shown in CPK, with the primary
ammonium group sandwiched between Trp183 where there is a cation- interaction
and Tyr234.  The indole nitrogen abuts the Tyr153 side chain.  Other binding site
residues are labeled.
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3.1.1 Roles of 5-HT3R binding-site tyrosine residues
Tyr 141 does not play a critical role in 5-HT3R agonist binding or gating, but it
may be involved in antagonist binding and receptor assembly.  The recent structure of
AChBP bound to agonists shows that the residue equivalent to Tyr141 (Leu 102)
hydrogen bonds to nicotine via a water molecule.22  In the homology model of the
5-HT3R, Tyr 141 does not contact 5-HT (and indeed in AChBP, residue Leu 102 does not
contact carbachol), but this does not preclude from it interacting with larger antagonists
and/or to another residue in the binding pocket, perhaps during subunit folding to assist
its correct formation.
Tyr 143 is a sensitive residue in that it can only be replaced by a limited number
of alternative amino acids to form functional receptors.  Data from these mutant receptors
(no change in [3H]granisetron binding affinity and a large change in EC50) combined with
the modeling data (no interaction with 5-HT) strongly suggest that Tyr 143 forms a
hydrogen bond between two regions of the receptor that is essential for receptor gating.
The modeling data further suggest that this bond may be between the hydroxyl group and
the backbone carbonyl group of Trp 183, which has been previously suggested by
Maksay et al.19  Previous data have also shown the importance of this residue in 5-HT3R
function13, and the equivalent residue in AChBP (Arg 104) has been shown to make
contact with carbachol.22
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Figure 3.6.   (a) Model of the 5-HT3R binding site in the closed state; Tyr 143 and
Tyr 153 are 3 Å closer to the center of the pocket than in the open state model.  (b)
Model of the 5-HT3R binding site in the open state with 5-HT (purple) docked,
showing potential new hydrogen bonds formed by Tyr143 and Tyr153.  (c) Model
of the 5-HT3R binding site in the open state with granisetron (orange).  Granisetron,
however, is most likely to bind to the closed state and, thus, there may be some
inaccuracies in this model.  Nevertheless, granisetron in this orientation would fit
into the closed state model, where it would be within 3Å of Tyr 153 but further
from Tyr 143.  (d) Rotated model a with 5-HT (purple) docked in the same position
as in b.  Steric interference with Tyr 143 and Tyr153 ( both green) would not allow
5-HT to be docked in this position.
The data also strongly suggest that Tyr 153 forms a hydrogen bond, and that this
bond plays a role in both binding and gating.  The equivalent residue in AChBP (Met
114) makes contact with both carbachol and nicotine22, and data from other studies also
suggest that it is involved in gating.  Tyr153Ala mutant receptors display unusual
response and desensitization kinetics13, and mutation of the aligning residue in the
GABAA receptor ?-subunit (Thr 142) resulted in the antagonist flumazenil acting as a
partial agonist.23  Interestingly, the equivalent residue in the 5-HT3B subunit is histidine.
24
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Thus, heteromeric (A plus B) receptors would also have a residue with the potential to
hydrogen bond in the binding site at this position.
Thus, our data show that the hydrogen bonds formed by Tyr 143 and Tyr 153 are
critical for correct receptor function, suggesting these bonds play an important role in the
conformational change leading to gating.  This could be because they stabilize the bound
state of the receptor and/or provide the energy required for protein rearrangement.
An aromatic residue at position 234 is essential for 5-HT3R function.  Indeed,
conservation of an aromatic residue at the aligning position among all 5-HT3R subunits—
and in fact all Cys-loop receptors— indicates the importance of this aromatic group
which appears to play a vital role as part of the “aromatic box” proposed to be critical for
agonist binding in all members of this LGIC family.25  However, a substituent at the 4
position appears to be important solely for gating because antagonist binding is
unaffected by removal of the Tyr 234 hydroxyl, and the docking data suggest that there is
no interaction between this group and 5-HT.8  The effect is steric because hydroxyl and
bromine which have similar sizes yield optimum function, whereas smaller substituents
such as fluorine and hydrogen are less effective.
3.1.2 A model for initiating gating
The differences observed between AChBP x-ray crystal data and nAChR cryo-
electron microscopy data suggest that AChBP better represents the open rather
than the closed state of the receptor.3  Thus, the docking of 5-HT into the homology
model of the 5-HT3R binding site as shown in Figure 3.5 is likely to be broadly accurate,
whereas removal of 5-HT from this structure would not be a good representation of the
closed state.  Data from Unwin and coworkers show that in this region, the residues
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equivalent to Tyr 143 and Tyr 153 are closer to the residues equivalent to Trp 183 and
Tyr 234 in the unbound (closed state) nAChR compared with AChBP (open-like state).3
These changes in distance are likely to be only a few ångstroms, because the binding site
is close to the point around which the inner and outer loops of the subunit pivot.  Shown
in Figure 3.6 is a homology model of the 5-HT3R binding site in the closed state based on
Unwin’s data.  Here, both Tyr 143 and Tyr 153 are 3 Å closer to the center of the binding
pocket.  We propose that 5-HT entering the pocket forms a cation-? interaction with Trp
183 and in so doing, displaces Tyr 143.  The hydroxyl of Tyr 234 ensures that Tyr 143
moves toward and subsequently, hydrogen bonds with the backbone carbonyl of Trp 183
and not with another E loop residue, as might be the case if formation of the alternative
rotamer was not prevented by the 234 hydroxyl group.  Tyr 153 is also relocated as 5-HT
enters the pocket, assisted by the hydrogen bond it forms with the indole amine on 5-HT.
These two residues  (Tyr 143 and Tyr 153) are located on separate ?-sheets linked by a
turn and therefore, their combined movement could provide considerable torsional force.
Combined with energy provided by the formation of hydrogen and other bonds, this
could initiate the twist that triggers the conformational change.
Some support for this hypothesis comes from docking studies with the 5-HT3R
antagonist granisetron, which when bound does not induce the conformational changes
associated with receptor gating.  A recent report by Maksay and coworkers suggests that
granisetron docked into a homology model of the 5-HT3R binding site does not approach
Tyr 143, but does come relatively close to Tyr 153 and interacts strongly with the
aromatic group of Tyr 234.19  Docking studies performed by the Lummis group
(unpublished observations) similarly reveal potential interactions of granisetron with
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Tyr?234 and Tyr 153, but not with Tyr 143.  One orientation of granisetron that was
observed, and is similar to that reported by Maksay and coworkers is shown in Figure
3.5.  Granisetron in this orientation would also fit comfortably into the closed state
model, and indeed, it may hydrogen bond with the hydroxyl of Tyr 153 (3 Å distant) in
this model.
Additional support comes from reports of movement in the nAChR binding site2, 3,
26 and in the GABAA receptor
27, which is likely to be similar in all Cys-loop receptors.
However this has not yet been confirmed as no ligand–free atomic resolution structure of
AChBP has yet been resolved.
3.4 Conclusion
In summary, the data obtained from introducing subtle changes to tyrosine
residues in the 5-HT3R binding site— combined with those obtained from models of the
binding pocket— have shown distinct roles of each of these residues in the binding site.
Combining these data with those from a model of the binding pocket has allowed us to
generate a hypothesis of the mechanism that triggers the conformational change leading
to channel opening.  The data therefore show the power of unnatural amino acid
mutagenesis in providing high-precision information that is highly complementary to
modeling efforts.  In addition, given the structural and functional similarity of ligand-
gated ion channels, we believe the proposed mechanism of conformation change
(agonist-stimulated movement of the binding loops combined with the formation of novel
hydrogen bonds) will be broadly similar in all members of the family.
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3.5 Methods
3.5.1 Mutagenesis and preparation of cRNA and Oocytes
Mutant 5-HT3AR subunits were developed using the eukaryotic expression vector,
pcDNA 3.1 (InVitrogen, Abingdon, U.K.), containing the complete coding sequence for
the 5-HT3A(B) subunit from NIE-115 cells as previously described.
28  Mutagenesis
reactions were performed using the Kunkel method29 and confirmed by DNA sequencing.
Wild type (WT) and mutant receptor subunit coding sequences were then subcloned into
pGEMHE plasmid.16  This was linearized with Nhe1 (New England Biolabs) and cRNA
synthesized using T7 mMESSAGE mMACHINE kit (Ambion).  Oocytes from Xenopus
laevis were prepared and maintained as described previously.11
3.5.2 Synthesis of tRNA and dCA-amino acids
Unnatural amino acids were chemically synthesized as nitroveratryloxycarbonyl
(NVOC) protected cyanomethyl esters and coupled to the dinucleotide dCA, which was
then enzymatically ligated to 74-mer THG73 tRNACUA as detailed previously.
30
Immediately prior to co-injection with mRNA, tRNA-aa was deprotected by photolysis.31
Typically, 5 ng mRNA and 25 ng tRNA-aa were injected into Stage V-VI oocytes in a
total volume of 50 nl.  For control experiments, mRNA was injected 1) in the absence of
tRNA and 2) with the THG73 74-mer tRNA.  Experiments were preformed 18-36 h post
injection.
3.5.3 Characterization of mutant receptors
5-HT-induced currents were recorded from individual oocytes using two-
electrode voltage clamp with either a GeneClamp 500 amplifier or an OpusXpress system
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(Axon Instruments, Inc., Union City, CA).  All experiments were performed at 22-25º C.
Serotonin (creatinine sulphate complex, Sigma) was stored as 25 mM aliquots at -80°C,
diluted in calcium-free ND96, and delivered to cells via computer-controlled perfusion
systems.  Glass microelectrodes were backfilled with 3 M KCl and had a resistance of
approximately 1 M?.  The holding potential was -60 mV unless otherwise specified.  To
determine EC50s, 5-HT concentration-response data were fitted to the Hill equation,
I?=?(Imax[A]
n)/(EC50
n + [A]n), where Imax is the maximal peak current, [A] is the
concentration of agonist, and n is the Hill coefficient.
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 Chapter 4. Conserved prolines in the M2-M3 loop
4.1 Introduction
Ligand-gated ion channels (LGIC) are highly dynamic proteins, undergoing
multiple conformational transitions among various states.  Their primary function is to
transduce a chemical signal— binding of a small molecule— into an electrical signal—
ion flux across the cell membrane.  They accomplish this feat through a global
reorganization of their quaternary structure.  Agonist binding to these proteins initiates a
series of conformational changes resulting in the opening of an ion permeant channel
across the cell membrane.  This process, linking agonist binding to the open conductance
state of the receptor, is termed gating.1-3  From a molecular perspective, this represents a
fairly amazing process.  The agonist-binding site and channel gate are separated by
almost 50 Å and nearly 100 amino acids of the protein’s primary sequence.  Thus, the
number of steric and noncovalent interactions driving this conformational transition is
significantly greater than that traditionally considered in the conformational analysis of
organic molecules.  Although advances in areas such as molecular dynamics have
certainly broadened the theoretical framework necessary for conformational analysis on
this scale, molecular details of the gating process still remain poorly understood.
Study of the gating process in LGICs has lacked an essential ingredient: structural
information.  This has made it difficult to relate functional changes observed in structure-
function studies to specific structural transitions associated with the gating process.
However, with recent publications of the AChBP crystal structures4, 5 and Nigel Unwin’s
structure of the transmembrane domains derived from 4 Å cryo-electron micrographs
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(cryo-EM) of the Torpedo nAChR,6 we may finally have sufficient structural information
to elucidate some of the molecular events of the gating mechanism.
Presumably, local conformational changes at the binding site (arising from agonist
binding) initiate the gating mechanism.  It is believed that rather than communicating
these changes sequentially through the primary sequence of the protein, intermediate
functional domains link binding site changes to the receptor gate.7  Evidence from several
studies highlights the possibility that the functional interface between the extracellular
and transmembrane domains is formed by interacting loops contributed by each domain.
Both biophysical studies and structural data point to two loops: the Cys loop and ?1-?2
loop in the extracellular domain as important components of the gating pathway.6, 8  In a
recent study where chimeric receptors were constructed by replacing the extracellular
domain of the 5-HT3R with the AChBP sequence, functional receptors were observed
only in chimeras where both the Cys loop and the ?1-?2 loop contained the 5-HT3R
amino acid sequence.9  This work provides telling evidence that these loops may form
functional domains, coupling conformational changes at the binding site to the channel
gate.
Findings from several studies indicate that the Cys and ?1-?2 loops convey
structural changes in the extracellular domain to the channel gate through a direct
interaction with the M2-M3 loop— a short loop that connects transmembrane domains
M2 and M3 and projects above the extracellular membrane.2, 6, 8-10  The M2-M3 loop is an
appealing candidate because not only are there several studies supporting its involvement
in the gating process (discussed below), but the channel gate lies in M2.  Hence any
movement of M2 would likely involve conformational changes in this loop.  In the work
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presented in this chapter, nonsense suppression methodology is used to investigate the
functional role of two conserved prolines, 301 and 308, in the M2-M3 loop of the
5-HT3R.  This work has been a collaborative effort with the Sarah Lummis group at the
University of Cambridge .  Sarah Lummis performed all of the immunofluorescence
work and contributed significant effort to the electrophysiology experiments.
4.2 Transmembrane domains and the M2-M3 loop
As detailed in chapter 1, LGICs are formed by five subunits arranged in a
pentagonal array around a central pore.  Each subunit has four transmembrane domains as
identified by hydropathy analysis.  The cryo-EM structure of the transmembrane region
shows that each of these domains forms an ?-helix spanning the bilayer6 (Figure 4.1).
The M2 domain of each subunit lines the channel lumen with the side chains of Leu 9’
and Val 13’ in M2 (the convention for numbering residues in M2 starts with 1’ at the N-
terminal or cytoplasmic side), forming the channel gate.  These are thought to present a
hydrophobic barrier preventing the flow of ions.11  The overall structure detailed by the
cryo-EM images is supported by much of the previous biochemical and
electrophysiological work.  Indeed, several earlier studies proposed an ?-helical structure
for M212, 13, and Leu 9’ has long been thought to form the channel gate.14, 15  In addition,
several novel features predicted by the structure have also been suggested by earlier
work.  In Unwin’s structure, the M2 helix extends two turns above the membrane.
Results from GABAA studies using the substituted cystine accessibility method (SCAM)
showed a modification pattern consistent with an extended helix.16  The structure also
shows a water-filled crevice between M2 and M3 which previously had been suggested.17
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Figure 4.1.   Several views of the 5-HT3R as predicted by homology modeling.
Highlighted features: binding site (red), Cys loop (purple), ?1-?2 loop (orange),
M2 (green), M2-M3 loop (blue), Leu 9’ (yellow) and prolines 301 and 308 (blue
CPK in a-c and red CPK in d).  (a) Side view of entire receptor showing general
arrangement of extracellular and transmembrane domains.  (b) Single subunit
showing Pro 301 and 308, and transmembrane topology.  (c) Top view looking
down the pore from the extracellular side.  The cluster of residues (Leu 9’) forms
the channel gate.  (d) Transmembrane domains, Cys loop and ?1-?2 loop of a
single subunit showing relative location of the loop structures.
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Based on the cryo-EM data Unwin has proposed a model for the gating
mechanism in nAChR (and by extension all LGIC).6  The model posits that ligand
binding induces a 15º rotation of the ? subunits, which in turn, causes the tip of the ?1-?2
loop— Val 44 specifically— to contact the M2-M3 loop (docking into the hydrophobic
pocket formed by Ser 269-Pro 272 of the M2-M3 loop).  The torsional force provided by
this contact pivots the M2-M3 loop, thereby rotating M2 and gating the receptor.
Although this seems to be a plausible model for the gating process, as yet, there is still a
lack of experimental evidence to substantiate it.  Several of the details, however, are
supported by previous findings.
In the model, the M2-M3 loop plays a prominent role in the gating process.  It not
only serves as the direct link communicating conformational changes in the extracellular
domain to the channel gate, but also functions as a pivot point for the gating movement of
M2.  The M2-M3 loop has long been speculated to be part of the gating pathway.
Mutagenesis studies in the GlyR and nAChR showed that mutations in this loop could
decouple agonist binding and channel gating.18-22  More detailed single-channel studies in
the nAChR demonstrated that mutations in the M2-M3 loop affect the gating equilibrium
and do not change the binding equilibrium.23  These studies also showed that the effects
of mutations in the loop were dependent on their position in the primary sequence of the
loop with one mutation increasing the gating rate and a similar substitution at the adjacent
residue decreasing the rate.  SCAM studies in both the GlyR and GABAA have shown the
M2-M3 loop becomes more water accessible during channel gating, indicating that it
undergoes a conformational change during the process.16, 24
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A recent study in GABAA points to a direct interaction between the M2-M3 loop
and the Cys loop during the gating process.8  This study swapped charged residues
between the Cys and M2-M3 loops to show that an electrostatic interaction between a
Lys in the M2-M3 loop and a conserved Asp in the Cys loop is formed during gating.
Interestingly, this Lys is not conserved in either the nAChR or 5-HT3R, and similar
studies in the GlyR did not show the same interaction10— raising the possibility that there
may be subtle variations in the gating mechanism for each of the Cys-loop receptors.
Unwin’s model emphasizes an interaction between the ?1-?2 loop and M2-M3.  It is very
likely that M2-M3 interacts with both of these extracellular loops.  Inspection of the
structure in Figure 4.1d shows that the Cys and ?1-?2 loops bracket M2-M3, and the
chimeric studies point to a need for both loops in coupling agonist binding and channel
gating.  Thus, while the exact role the M2-M3 loop plays is not clear, the cumulative
evidence strongly supports it being functionally important in the gating pathway.
4.3 Potential dynamic role of proline
One interesting feature of the M2-M3 loop in the 5-HT3R is the presence of two
proline residues (Figure 4.2).  Pro 301 is conserved in all Cys-loop receptors and is
located roughly two helical turns below the C-terminal end of M2 (Figure 4.1).  Pro 308
is conserved in all of the cation-selective receptors (nAChR and 5-HT3R) and is located
two residues after the C-terminal end of the extended M2 helix (Figure 4.1).  This proline
aligns with Pro 272 in the nAChR, which in Unwin’s model forms part of the
hydrophobic pocket into which the ?1- ?2 loop docks.  Proline has several special
features (discussed below) that make it an intriguing consideration in terms of the gating
process.
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GABA TSLGITTVLTMTTLSTIARKSLP-KVSYVTAMDLFVSVCFIFVFAALMEYGTLH
GLYR VGLGITTVLTMTTQSSGSRASLP-KVSYVKAIDIWMAVCLLFVFSALLEYAVNF
5HT3 VSFKITLLLGYSVFLIIVSDTLPATAIGTPLIGVYFVVCMALLVISLAETIFIV
ACHA MTLSISVLLSLTVFLLVIVELIPSTSSAVPLIGKYMLFTMVFVIASIIITVIVI
Extended M2
9'
M3
M2-M3 loop
301 308
Figure 4.2.   Sequence alignment of the murine sequences for ?1 GABAA, ?1 GlyR,
5-HT3AR, and ?1 nAChR.  Pro 301, Pro 308, and secondary structural domains are
indicated.  The M2 helix as identified by hydropathy analysis is shown in green,
and the extended helix as predicted in the cryo-EM structure is designated by the
green box. Pro 301 is conserved in all Cys loop receptors, Pro 308 is conserved in
the cation-selective receptors.
Proline is unique among the 20 standard amino acids in that its side chain is
covalently bonded to the ?-amino group.  This cyclic structure severely limits the main
chain conformations proline can adopt.  In terms of the backbone dihedral angles, ? and
?, proline is the most conformationally restricted amino acid.  The cyclic structure fixes
the ? dihedral at -65º±25º and leaves the ? dihedral hindered with two local minima near
–55º and 145º, though surveys of the protein databank show that ? values around 80º are
also common.25, 26  Another consequence of the cyclic structure is that the secondary
peptide bond formed with the nitrogen of proline lacks a hydrogen, resulting in the loss of
a hydrogen-bond donor at prolyl backbone sites.  Due to its conformational limitations
and the absence of an amide hydrogen, proline is rarely found in periodic secondary
structure such as ?-sheets or ?-helices.25, 26  In fact, in globular proteins, proline is
considered the classic helix-breaker.
Interestingly proline is found with anomalous frequency in the putative helices of
integral membrane receptors and transport proteins.27  The reasons for this are not yet
clear, but it has lead to wide speculation that proline is important in the structure and
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function of these proteins.28-30  The potential importance of proline is evidenced by the
recent observation that mutations of proline have one of the highest phenotypic
propensities in the analysis of TM sequences from the Human Gene Mutation Database.31
As a result of its lacking a hydrogen-bond donor and the local steric restrictions it
presents, proline, when found in helices imparts a 25º kink to the helix trajectory.32, 33
From a structural standpoint, modeling studies have shown that this kink can serve to
stabilize transmembrane helix bundles by increasing the van der Waals contact between
the helices.34  It is also hypothesized that a proline kink may serve a dynamic role because
it removes at least one hydrogen-bonding pair (between the NH of proline at i and the
carbonyl O at i-4) and often leads to loss of a second pair (the NH of i+1 and the
carbonyl O of i-3).28, 29  This allows the two ends of the helix to pivot independently.
Thus, the proline kink could function as a hinge point in the conformational changes of
ion channel function.
Another interesting feature that has generated much speculation about proline is it
is the only standard amino acid for which the cis peptide bond is energetically
accessible30 (Figure 4.3).  Surveys of the protein data bank show that roughly 5-6% of all
prolines are in the cis conformation, as opposed to the other amino acids for which less
than 1% are cis.35, 36  Proline’s ability to adopt the cis conformation arises largely due to
destabilization of the trans conformation from steric conflicts between C? of proline and
C? of the preceding residue.  From a structural standpoint, cis proline is found in several
types of ?-turns, where the protein chain direction is reversed over a short distance.26, 37
This characteristic of proline may also play a dynamic role in that cis/trans isomerization
of prolyl peptide bonds may function as a conformational switch.38  Recently, several
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cis/trans proline switches have been elucidated in globular proteins, most notably the
tyrosine kinase Itk where isomerization shuttles the protein between different active
states.39-41
N
O
R
N
O
O
R
O
trans cis
Figure 4.3.  Schematic of trans and cis conformations of the prolyl peptide bond.
It has long been speculated that cis/trans isomerization of prolyl peptide bonds
could be involved in the gating pathway of ion channels.27, 30  Indirect evidence has come
from studies on gap junction proteins42, but to date, there is no clear experimental
evidence supporting this hypothesis.  However, given the anomalous frequency of proline
in transmembrane helices and the recent demonstrations of proline switches, this still
remains an attractive hypothesis.  Another potential way in which proline could facilitate
the conformational changes associated with ion channel gating is in shuttling between
favored states at the hindered ? angle.  NMR studies on model peptides corresponding to
the second intracellular loop of the vasopressin receptor (a GPCR) have demonstrated a
conformationally heterogeneous proline, where the ? angle flipped between two stable
conformations.43  This proline is conserved throughout the GPCR family and is believed
to be important for coupling to G proteins.  Thus, this may represent a general motif
where proline functions as a conformational switch without cis/trans isomerization.
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4.4 Experimental design
A series of proline analogs was selected to evaluate the functional role of Pro 301
and Pro 308 in the 5-HT3R (Figure 4.4).  The analogs were chosen to assay specific
features of proline’s structure and function, and many of the analogs have been
previously studied in model peptides, providing some quantitative background data for
interpreting our results.44-50  In addition some of the analogs have been used in previous
nonsense suppression studies to evaluate a conserved proline in the M1 domain of the
nAChR and 5-HT3R.
51, 52
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Figure 4.4.  Structures of the amino acids used to probe Pro 308 and Pro 301.
In many ways, proline is an ideal target residue for structure-function studies with
unnatural amino acids, as it has several features that can be readily tested with minor
perturbations.  Ring size and the attendant flexibility can be tested with the 4- and
6-membered ring analogs, Aze and Pip, respectively.  The ring of proline displays two
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stable conformations: endo pucker and exo pucker (discussed below).  This feature of
proline can be tested with the fluoro-prolines, which each prefer a different puckered
conformation.47, 53  The hydrogen bonding properties can be examined using backbone
ester substitutions with hydroxy acids or N-methyl amino acids.51  The latter can also be
used to assay the potential role of the secondary prolyl amide.  In addition N-methyl
amino acids mirror many of the conformational features of proline, but lack the rigid ring
structure.  Finally the potential of cis/trans isomerization can be readily tested using
analogs of proline that are selective for a particular conformation (cis-selective: Aze, Pip,
and dmP46, 48; trans-selective: trans-3-Me-Pro, 2-Me-Pro, and 2,4-methano-Pro44, 49, 54).
4.5 Results
4.5.1 General experimental details
Both unnatural and natural amino acids were incorporated into positions 301 and
308 of the 5-HT3R using in vivo nonsense suppression methods, and mutant receptors
were evaluated electrophysiologically55.  The whole-cell currents induced by the
application of 5-HT were measured by two-electrode voltage clamp techniques.  Non-
functional receptors were assayed for surface expression using immunofluorescent
imaging.  The functional effects arising from the introduced mutations were determined
from the dose-response relations and the macroscopic rate constants for receptor
activation and deactivation.  Macroscopic rate constants were determined from the single-
exponential fits of the whole-cell current traces using pCLAMP 9.0 analysis software.  In
all experiments, the 5-HT3AR homomer was used.
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4.5.2 Control experiments for 301 and 308
Initial experiments at both 301 and 308 focused on several important controls:
ensuring no protein was produced through any read-through of the UAG-containing
mRNA, and recovery of the wild type receptor through nonsense suppression.  Injection
of either of mRNA with the UAG stop codon at 301 or 308 resulted in no 5-HT induced
currents.  In addition, injection of UAG-containing mRNA and uncharged tRNA
produced no 5-HT induced currents at either site.  Both of these controls indicate that in
the absence of charged tRNA functional receptors are not produced by read-through of
the UAG-containing mRNA.  Injection of UAG-modified mRNA with aminoacyl tRNA-
Pro into oocytes resulted in receptors with functional properties similar to wild type,
EC50s of ~1.2 µM and Hill coefficients of ~2 (Table 4.1 and 4.2).
4.1.3 Electrophysiology results for substitution at 308
4.1.3.1 Dose-response data
In all, 15 different residues were attempted at position 308.  Interestingly, nine of
these did not produce functional receptors (see Table 4.1), indicating this is a fairly
stringent position.  All mutations that produced functional receptors were close analogs
of proline and maintained a cyclic structure.  The dose-response data show that with the
exception of dmP, the functional mutations lead to only modest changes in EC50 (Figure
4.5 and Table 4.1).  The two ring-size analogs, Aze and Pip, lead to 3- and 1.7-fold
reductions in EC50, respectively, whereas the two fluoro-prolines, cis-4-F-Pro and
trans-4-F-Pro, produced EC50s very near wild type.  In the case of dmP, however, a
23-fold reduction in EC50 was observed.  This finding is suggestive of the possibility that
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a cis-proline is functionally important at position 308, as model peptide studies have
shown dmP to prefer the cis-amide isomer by ~1.1 kcal/mol relative to trans.48 It is also
possible that given the increased sterics of dmP, this residue alters the conformation of
the M2-M3 loop, biasing it towards the open state conformation.
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Figure 4.5.   Dose-response relations for Pro 308 mutants.  (a) Pro (circles), Aze
(triangles), Pip (squares), and dmP (diamonds).  (b) Pro (circles), cis-4-F-Pro (squares),
and trans-4-F-Pro (triangles).
Further analysis of the dose-response data shows a strong correlation between the
EC50 for the mutant receptors and the cis preference of the proline analogs (Table 4.2).
Figure 4.6 shows a plot of ??G EC50 (mutant – wt) versus ??G for the cis preference of
the analogs relative to proline.  The linear correlation seen for the plotted values provides
additional evidence that a cis proline at 308 may be functionally important in the gating
mechanism.
Several underlying assumptions in this plot, however, should be noted.  The
quantity EC50 is not a true equilibrium constant.  It is a composite of equilibria for both
binding and gating.  Our assumption, however, is that changes in EC50 with these mutants
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reflect changes in the gating equilibrium and do not affect binding.  Support for this
assumption comes from single-channel studies which demonstrated that mutations in this
region of the nAChR solely affected gating.23  Furthermore, position 308 is ~30 Å from
the binding site, and thus, mutations here are not likely to affect agonist binding.  The
??G values for the cis preference of the analogs come from several literature studies and
were determined for small model peptides.46-48  It is known that many factors including
both the local protein sequence and longer-range interactions can affect the cis preference
of proline.36, 37, 56  We assume, however, that these factors will be similar for all the
analogs considered, and thus, the trend in cis preference for the analogs will not be overly
distorted from that seen in the model studies.  Finally, this plot, although spanning two
orders of magnitude in EC50, shows that the data is clustered into two regions.  The plot
requires an intermediate data point between Aze and dmP, as linear fits of data clustered
into two regions can be misleading.
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Figure 4.6.  Plot of ??G EC50 for the Pro 308 mutants versus ??G for the cis
preference of the analogs relative to proline.  Equation for the linear fit and R value
are shown at the top.
Table 4.1 Dose-response data and macroscopic rates for the Pro 308 mutants
Residue EC50±SEM (µM) Hill±SEM Act. rate±SEM (s
-1) Deact. Rate±SEM (s-1)
Pro 1.29  ± 0.07 2.04 ± 0.18 2.85 ± 0.91 0.03 ± 0.01
Aze 0.42  ± 0.03 1.56 ± 0.19 0.48 ± 0.06 0.02 ± 0.01
Pip 0.75  ± 0.06 2.16 ± 0.28 8.61 ± 0.27 0.29 ± 0.03
cis4FPro 1.16  ± 0.12 1.74 ± 0.27 5.95 ± 0.75 ND
trans4FPro 1.38  ± 0.06 2.53 ± 0.23 7.22 ± 0.34 ND
dmP 0.055 ± 0.01 0.77 ± 0.1 2.93 ± 0.69 ND
Ala NR NR
Gly NR NR
Val NR NR
Vah NR NR
Sar NR NR
NMeLeu NR NR
trans3MePro NR NR
2,4MPro NR NR
2MePro NR NR
ND = not attempted, NR = no response to concentrations up to 1 mM 5-HT
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Table 4.2. Thermodynamic data for proline analogs
Residue %cis Kcis ?Gcis (kcal/mol) ??Gcisa (kcal/mol)
Reference 47
Pro 17 0.20  0.96  0.0
trans4FPro 12 0.14  1.17  0.21
cis4FPro 28 0.39  0.55 -0.40
Reference 46
Pro 6 0.06  1.67  0.0
Pip 13 0.15  1.13 -0.54
Aze 20 0.25  0.82 -0.85
Reference 48
Pro 13 0.15  1.13  0.0
dmP 87.5 7.0 -1.15 -2.28
a??Gcis for analog/proline
4.1.1.2 Incorporation of dmP at 308 shows blockable leak currents
Experimental support for the conclusion that the dmP 308 mutant stabilizes the
open channel conformation of the M2-M3 loop comes from the observation that oocytes
expressing dmP-containing receptors showed a continual increase in leak current
following initial receptor activation (Figure 4.7).  This leak was almost completely
reversible by the open-channel blocker TMB-8, indicating the leak current was associated
with receptor activation and not with any oocyte specific process.  This finding suggests
that upon activation dmP locks the channel in the open state.  Furthermore, the lowered
EC50 and blockable leak current seen with the dmP mutant indicate that Pro 308
undergoes a conformational change associated with the gating pathway.
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Figure 4.7.   Current traces for dmP at position 308, showing the TMB-8 blockable
leak currents seen after receptor activation by 5-HT.  Bars represent 5-HT
application.
4.1.1.3 Macroscopic rates
An interesting feature of these studies is that all functional mutants at 308 lead to
changes in the macroscopic rates of activation and desensitization (Table 4.1).  Figure 4.8
shows representative traces illustrating the altered rates.  The fluoro-prolines and dmP
lead to ~2-fold increases in the macroscopic activation rates.  Pip lead to 3- and 8-fold
increases in the rates of activation and deactivation, respectively.  Aze was the only
mutation to show decreased rates, producing a 6- and 1.7-fold decrease in activation and
deactivation, respectively.
The rates for Aze, Pro and Pip match the trend in ring size with the 4-membered
ring (Aze) slower than the 5 (Pro) and 5-membered ring slower than the 6 (Pip).  It is
possible that this trend in rates reflects differences in either ring flexibility or ring
conformation among these residues.  The potential importance of the ring conformation is
supported by the changes seen with the fluoro-prolines, as cis-4-F-Pro favors an endo
ring pucker and trans-4-F-Pro favors an exo ring pucker (Figure 4.9).47, 53, 57, 58  (The
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proline ring exhibits two preferred ring conformations or puckers: endo where C? is
flipped cis to the carboxy group and exo where C? is flipped trans to the carboxy group ).
Thus, small changes in the ring conformation may cause subtle differences in the gating
pathway.
200 nA
40 s
trans4FProcis4FProPro Pip Aze dmP
Bars = 5-HT application at 5 x EC50
Figure 4.8.   Current traces showing the altered rates of activation and deactivation
for the 308 mutants.  Bars represent application of 5-HT at 5 times EC50 of the
respective mutant.
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Figure 4.9.   Schematic showing the two stable ring conformations (endo and exo)
in proline and the preferred ring conformation for the 4-fluoro prolines.
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4.1.4 Surface expression of nonfunctional mutants at 308
In order to rule out the possibility that the nonfunctional mutants arose from
injection of hydrolyzed aminoacyl-tRNA, all tRNAs were analyzed by MALDI-TOF
mass spec to ensure that the aminoacyl linkage was still intact.59  In addition, all the
attempted residues have successfully been incorporated into other sites in either the 5-
HT3R or nAChR using nonsense suppression.
51, 52  Thus, it seems very doubtful that the
lack of functional receptors was caused by any incompatibilities with the ribosome or
translation machinery.
The cell-surface expression of the non-functional mutants was examined by
immunofluorescence to determine if these mutations had impaired receptor assembly and
processing, or if they produced surfaced expressed but silent receptors.  This work was
performed by Sarah Lummis.  Oocytes expressing the mutant receptors were fixed in 4 %
paraformaldehyde, placed in glycerol and strored at –80º C.  After thawing, oocytes were
labeled with the primary antibody pAB120, washed, and then labeled with the secondary
antibody, Cy5-conjugated anti-rabbit IgG.60  Immunofluorescence was observed with a
Nikon optiphot or a confocal (BioRad-MRC600) microscope.
All of the nonfunctional mutants showed surface labeling, indicating that these
mutations had lead to silent receptors (Figure 4.10).  The fact that the natural amino acids
Gly, Ala, and Val produced surface expressed but silent receptors supports the idea that
this position requires a conformationally restricted residue.  However, even the N-methyl
amino acids Sar and N-Me-Leu were silent, and as these residues replicate some of the
conformational restrictions imposed by proline but lack the ring, clearly the more rigid
ring structure is important.  The fact that both the N-methyl residues and Vah were silent
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rules out the possibility that the unique hydrogen bonding characteristics of Pro 308 are
important.  This latter possibility was found to be the case in earlier studies of a
conserved proline in M1 of both the nAChR and 5-HT3R.
51, 52  These studies found that
replacement of this proline with a hydroxy acid produced functional receptors with wild
type characteristics.
Not all of the ring-containing residues produced functional receptors.  2-Me-Pro,
trans-3-Me-Pro and 2,4-methano-Pro were all silent.  This suggests that the rigid ring
structure is not sufficient to produce functional receptors.  Both 2-Me-Pro and
2,4-methano-Pro are highly selective for the trans amide bond, lending further support to
the possibility of a functionally important cis peptide bond at position 308.49, 54  Trans-3-
Me-Pro, on the other hand, is a fairly close analog of proline and studies have shown that
it closely mirrors proline’s cis preference.49  One difference for trans-3-Me-Pro is that it
has a higher barrier to cis/trans isomerization.26, 44  This supports the conclusion that
cis/trans isomerization at Pro 308 is mechanistically important in the gating pathway.
Additionally, the reason for the higher barrier in trans-3-Me-Pro is believed to arise from
its inability to form a hydrogen bond between the prolyl N and the NH at position i+1.
This hydrogen bond has been shown to catalyze isomerization of prolyl-peptide bonds,
increasing the isomerization rate 260-fold in model studies.61, 62  One of the concerns for
suggesting cis/trans isomerization at Pro 308 is that this isomerization may proceed at too
slow a rate to be functionally viable in receptor gating, as the latter process occurs on the
µs to ms timescale and isomerization is more often on the seconds timescale.  Thus, the
results with trans-3-Me-Pro point to the possibility that the formation of this hydrogen
bond may catalyze the isomerization at Pro 308.  It should also be noted that many
90
researchers have hypothesized that long-range protein interactions could increase the
isomerization rate of proline, to make it a viable conformational switch in fast-acting
processes.30, 56
Aside from the trends in cis and trans preference, the immunofluorescence
findings show that incorporation of proline analogs substituted at the 2 or 3 position
results in receptors where agonist binding and channel gating have been decoupled.  A
possible explanation is that steric bulk on this side of the proline ring may disrupt the
proper orientation of the M2-M3 loop.  Alternatively, bulk on this side of the ring may
interfere with specific interactions of the proline ring, possibly even with interactions
between Pro 308 and one of the extracellular loops.  This latter speculation could fit with
Unwin’s model in that steric bulk at the 2 or 3 position of the proline ring may prevent
docking of the ?1- ?2 loop into the hydrophobic pocket of the M2-M3 loop.
WT  2-Me-Pro 2,4-MPro trans-3-Me-ProBlank
Figure 4.10.   Immunofluorescent images of the nonfunctional 308 mutants.
Visible labeling of mutants expressing trans-selective proline analogs demonstrates
these receptors are expressed at the cell surface.
4.1.5 Poor expression of dmP and Aze at 308
A final observation to note in the studies of Pro 308 is that both dmP and Aze
displayed very inconsistent expression.  In all, approximately 200 oocytes from 10
different batches were tried for each of the residues.  For dmP, expression was seen in
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only 9 oocytes and with Aze, 13 oocytes showed expression. Several avenues were taken
to increase the expression in these two mutants: incubation at different temperatures,
expression with the 5-HT3B subunit, and double injection.  None, however, lead to any
increase in expression.
Both of these unnaturals present steric and conformational demands.  In dmP
significant steric bulk has been introduced adjacent to the nitrogen.  This may interfere
with the efficiency of the peptidyl-transfer reaction during translation.  In Aze, the
conformational restrictions imposed by the 4-membered ring may interfere with
processing and assembly.  This latter concern could also be a problem with dmP mutants.
It is known that the folding of the 5-HT3R is dependent on the activity of the proline-
peptidyl isomerase cyclophilin A (CypA).63  It is plausible that dmP and Aze are
inefficient substrates for CypA, which would certainly lead to a reduction in the
expression for both mutants.  In addition, studies of the cystic fibrosis transmembrane
receptor have shown that mutations of proline residues embedded in transmembrane
regions can have a deleterious effect on the kinetics and robustness of folding.33
4.1.6 Substitution at 301
In all, 13 different amino acids were incorporated at position 301, and much like
with 308, only six produced functional receptors (see Table 4.3).  In contrast to the
substitution pattern at 308, however, residues not maintaining a cyclic structure produced
functional receptors at 301.  The dose-response data show that none of the functional
mutations lead to large changes in EC50. (Figure 4.11 and Table 4.3)  Substitution by Val
resulted in a 3-fold decrease in EC50.  The fact, that this standard residue which has a
hydrogen at the amide position and shows a strong preference for the trans-amide
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produced functional receptors with only a modest shift in EC50 indicates that neither the
special hydrogen-bonding properties of proline nor a cis-proline are important at this site.
Incorporation of Vah, dmP, and Pip at 301 lead to roughly 2-fold increases in EC50, and
incorporation of Aze lead to a 2-fold decrease in EC50.  Thus, aside from the Val
mutations, the dose-response data do not point to any special features of this site.
All functional mutations, however, did lead to increases in the macroscopic rates
of activation and deactivation (Figure 4.12 and Table 4.3).  Val, Aze and Pip resulted in
3- to 4-fold increases in the activation rates and 9- to 14-fold increases in deactivation
rates.  More dramatic rate increases were seen with dmP and Vah.  The former lead to 22-
and 68-fold increases in activation and deactivation, respectively, and the latter lead to
25- and 85-fold increases in activation and deactivation, respectively.  The only obvious
parallels between the two residues is that relative to proline and the other mutations, both
dmP and Vah have lower barriers for amide bond isomerization.  The results for Val,
however, make this a doubtful scenario.  Thus, position 301 does seem to be tuned for the
presence of proline, as all mutations were either non-functional or lead to rate increases.
Given that the cryo-EM structure of the transmembrane domains shows a kink in the
helix at Pro 265 (the homolog of 301), it seems possible that this proline may establish
the proper orientation of the M2 helix.  Thus, the changes we observe in the rates may
reflect alterations in the M2 helix kink and/or orientation.
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Figure 4.11.   Dose-response relations for Pro 301 mutants. Pro (open circles), Aze
(filled squares), Pip (filled circles), dmP (open triangles), Val (filled triangles), and Vah
(open squares).
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Bars = 5-HT application at 5 x EC50
Figure 4.12. Current traces showing the altered rates of activation and deactivation
for the 301 mutants.  Bars represent application of 5-HT at 5 times EC50 of the
respective mutant.
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Table 4.3 Dose-response data and macroscopic rates for the Pro 301 mutants
Residue EC50±SEM (µM) Hill±SEM Act. rate±SEM (s-1) Deact. Rate±SEM (s-1)
Pro 1.18 ± 0.02 2.12 ± 0.08 2.85   ± 0.91 0.02 ± 0.0005
Aze 0.68 ± 0.03 1.77 ± 0.11 10.75 ± 2.64 0.16 ± 0.021
Pip 1.73 ± 0.02 2.16 ± 0.04 12.45 ± 2.94 0.25 ± 0.026
Val 0.36 ± 0.02 2.82 ± 0.47 9.62   ± 2.07 0.13 ± 0.022
Vah 2.6   ± 0.62 1.27 ± 0.22 71.11 ± 5.66 1.46 ± 0.013
dmP 2.37 ± 0.54 1.12 ± 0.17 64.44 ± 4.48 1.15 ± 0.101
Ala NR NR
Gly NR NR
Sar NR NR
NMeLeu NR NR
trans3MePro NR NR
2,4MPro NR NR
2MePro NR NR
NR = no response to concentrations up to 1 mM 5-HT
4.6 Discussion
Agonist binding in ligand-gated ion channels initiates a series of conformational
changes that ultimately lead to opening of an ion permeant channel across the cell
membrane.  The molecular details linking binding to the channel gate some 50 Å away
remain largely unknown.  From a chemical standpoint, this is an intriguing consideration:
how does the noncovalent binding of a small molecule induce a dramatic structural
change in a multisubunit ~300 kDa protein?
Previous work has indicated a potentially prominent role for the M2-M3 loop in the
gating pathway.  This small loop connects the channel-lining domain (M2) with the M3
domain, and is an appealing candidate because of its location at the interface between the
binding and transmembrane domains (Figure 4.1).  To investigate the functional role of
the M2-M3 loop, we have probed two conserved prolines in this domain using unnatural
amino acids.  Our findings indicate Pro 301 and Pro 308 are functionally important in the
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gating pathway, and in particular the results at Pro 308 lend experimental support for a
recently proposed gating model
Based on cryo-EM data from the nAChR, the model posits that binding of agonist
induces a 15º rotation of the extracellular domains.6  This rotation leads to contact
between the ?1-?2 loop of the extracellular domain and the M2-M3 loop.  Specifically,
Val 44 docks into a hydrophobic pocket formed by Ser269-Pro 272.  This then provides
the torsional force for movement of the M2 domain and gating of the channel.  In the
model, the M2-M3 loop not only acts as the mechanical receiver of conformational
changes in the extracellular domain, but also serves as the hinge for the gating movement
of M2.  Pro 308 in the 5-HT3R aligns with Pro 272 of the nAChR.  This residue is
conserved amongst the cation-selective members of the Cys-loop family.  Our data
support a conformational change at Pro 308 during the gating process that is consistent
with this domain functioning as a hinge.
The data show that Pro 308 is a highly stringent site that requires a rigid ring
structure for proper receptor function.  Substitution by Ala, Gly, Sar, Val, Vah or N-
Me-Leu resulted in receptors that were expressed at the cell surface, but did not respond
to agonist, indicating these mutations decoupled agonist binding and channel gating.  A
rigid ring structure, however, is not sufficient.  Substitution by trans-3-Me-Pro,
2-Me-Pro, or 2,4MPro also leads to surfaced-expressed, yet nonfunctional receptors
(Figure 4.10).  This group of mutations shares a common characteristic in that they
disfavor the cis-amide isomer.  In model peptide studies, 2-Me-Pro and 2,4-methano-Pro
showed no detectable cis isomer, and trans-3-Me-Pro has a higher barrier to
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isomerization relative to proline.44, 49, 54  These results suggest the possibility that a cis-
peptide bond is functionally important at Pro 308.
This conclusion is supported by the dose-response data, where incorporation of the
cis-selective proline analog, dmP leads to a significant decrease in EC50.  Furthermore a
plot of ??G EC50 for the various mutants versus the ??G values for the cis preference of
the analogs relative to proline shows a linear correlation (Figure 4.6).  The correlation
between EC50 and cis preference is seen for over two-orders of magnitude change in EC50
and almost a 2.5 kcal difference in cis preference.  This is fairly compelling evidence for
a functionally important cis-proline at 308.
It is also possible that given the increased steric bulk of dmP, this residue is
altering the conformation of the M2-M3 loop in a way that biases the receptor towards
the open state.  The functional role of Pro 308, however, does appear to be dynamic, as
activation of the dmP mutants lead to an increase in the standing current that was
blockable by TMB-8 (Figure 4.7).  This standing current was seen only after initial
activation of the mutant receptors and grew progressively larger after each application of
5-HT.  This seems to indicate that once open the dmP mutant is slow to deactivate (i.e.
transiting to either the desensitized or closed state).  This result suggests that the gating
process involves a conformational change at Pro 308.  A consistent interpretation of this
finding combined with the immunofluorescence and dose-response data is that in the
resting closed state, Pro 308 is in the trans-conformation and during gating, it isomerizes
to the cis-conformation (Figure 4.13).  It is also possible that the functional changes we
see with the 308 mutants reflect a gating specific heterogeneity in the conformation of
Pro 308 that does not involve cis/trans isomerization.  Pro 308 may function as a
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conformational switch converting between two stable orientations of ?.  Our findings,
however, do support a dynamic role for Pro 308 in the gating pathway.
The results at Pro 301 are also suggestive of a role in the gating pathway.  Here,
however, we did not see large changes in EC50, but changes in the macroscopic rates.
This site is not as stringent as Pro 308 and the data do not suggest any obvious trend, as
both cyclic proline analogs, natural amino acids and the hydroxy acid Vah lead to
functional receptors.  The rate changes however suggest that indeed, the mutations were
affecting the gating pathway, possibly by changing the orientation or kink angle of the
M2 helix.
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cis Thr-Pro
trans Thr-Pro
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Figure 4.13.   Cartoon of a single 5-HT3R subunit depicting how trans to cis
isomerization could function as a hinge for movement of M2 (green) during gating.
The general gating mechanism is based on Unwin’s proposed model, where agonist
binding (red) induces a rotation of the extracellular domains.  This brings the ?1-?2
loop (orange) into contact with the M2-M3 loop (blue) causing the latter loop to
pivot.  Here the pivot is depicted as trans to cis isomerization of Pro 308 (blue
CPK).  The hinge movement in the M2-M3 loop allows rotation of M2 and gates
the channel.  Leu 9’, the gate, is shown in yellow CPK.  The open structure on the
right was generated by manually converting Pro 308 to the cis conformation.
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4.7 Future directions
In conclusion, our findings support a functional role for both Pro 301 and Pro 308
in the gating process of the 5-HT3R.  The results at Pro 308 in particular suggest this site
functions as a conformational switch during gating, which is consistent with Unwin’s
prediction that the M2-M3 loop serves as a hinge during the gating process.  Several
possibilities, however, could be pursued to strengthen this conclusion.  First, the plot of
??G EC50 versus ??G cis preference requires an intermediate data point between dmP
and Aze.  Experiments by Lori Lee with cis-5-tBu-Pro are currently underway to remedy
this concern.  Second, if Pro 308 does indeed function as a conformational switch (either
through cis/trans isomerization or converting between stable ? conformations) this is
likely to be a mechanism that is at least conserved in the nAChR, which also has a proline
at this site.  Thus, repeating these studies in the nAChR is a necessary validation of our
conclusions.  And third, for both the 301 and 308 studies the nAChR offers the possibility
to combine unnatural mutagenesis with single–channel experiments.  This would allow
better resolution of the mutational effects, and could provide telling information on how
these mutations perturb the gating mechanism.
4.8 Methods
4.8.1 Synthesis of dCA-NVOC-5,5-dimethylproline
Synthesis of NVOC-DL-5,5-dimethylproline was adapted from the procedure of
Magaard and coworkers64 (Scheme 4.1).
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Scheme 4.1   Adapted synthesis of NVOC-DL-5,5-dimethylproline.
4.8.1.1 1-Hydroxy-2-cyano-5,5-dimethylpyrrolidine
KCN (1.15 g, 17.6 mmol) was dissolved in 2.5 mL of water and cooled to –10º C.
To this was added 5,5-dimethyl-1-pyrroline N-oxide (1 g, 8.8 mmol) in 2.5 mL of water.
2 N HCl (25 mL) was added dropwise over one hour, then stirred at 0º C for 3 hours and
at room temperature overnight.  The pH was adjusted to 11 with 6 N KOH and the
solution was extracted with diethyl ether.  The ether extracts were dried over MgSO4 and
rotary evaporated to yield 0.92 g (75% yield) of a white powder. 1H NMR (300 MHz,
CDCl3) ? = 1.06 (6H, s), 1.67-1.84 (2H, m), 1.99-2.28 (2H, m), 3.92 (1H, t), 6.25 (1H, s).
13C NMR (75 MHz, CDCl3) ? = 19.4, 34.4, 54.8, 64.4, 120.5.  MS Calcd for C7H11N2O
139.18. Found: (ESI+) 141.0 [M+H+]+.
4.1.1.2 NVOC-DL-5,5-dimethylproline
1-Hydroxy-2-cyano-5,5-dimethylpyrrolidine (400 mg, 2.8 mmol) was hydrolyzed
in conc. HCl (1.6 mL) at 50º C for 5 hours and evaporated to a white solid.  After
evaporating from water two times to remove traces of HCl, the residue was dissolved in
20 mL of methanol/water 1:1 and hydrogenated over 10% Pd/C (120 mg) at 1 atm for 4
hours.  The reaction was filtered through celite to remove the catalyst and the solvent was
removed by rotary evaporation.  The product was then dissolved in 25 mL of
water/dioxane 1:1 and Na2CO3 (742 mg, 7 mmol) was added.  A solution of NVOC-Cl
(1.1 g, 3.9 mmol) in 25 mL water/dioxane was added dropwise and the mixture was
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allowed to stir.  After two hours, 50 mL of CH2Cl2 was added followed by 1 M (aq)
KHSO4 (25 mL).  The aqueous layer was extracted three times with 25 mL CH2Cl2.  The
organic extracts were combined, dried over MgSO4, and the solvent was removed by
rotary evaporation.  The crude product was purified by flash chromatography (silica,
50:50 hexane/ethyl acetate w/ 1% acetic acid) to give a bright orange solid (210 mg, 20%
yield). 1H NMR (300 MHz, CDCl3) ? = 1.40 (3H, s), 1.56 (3H, s), 1.79-2.08 (3H, m),
2.08-2.32 (1H, m), 3.91 (3H, s), 3.94 (3H, s), 4.50-4.56 (1H, m), 5.45 (2H, dd), 6.94 (1H,
s), 7.65 (1H, s).  13C NMR (75 MHz, CDCl3) ? = 25.3, 26.3,26.6, 39.5, 56.3, 56.5, 60.8,
61.8, 64.1, 107.9, 109.2, 128.2, 140.4, 147.7, 153.8, 155.1, 178.1.  MS Calcd for
C17H22N2O8 382.37. Found: (ESI
-) 381.2 [M-H]-.
4.1.1.3 NVOC-DL-5,5-dimethylproline cyanomethyl ester
Under positive argon pressure, a dried flask was charged with a solution of
NVOC-5,5-dimethylproline (75 mg, 0.19 mmol) dissolved in 3 mL of dry DMF.
Triethylamine (66 µL, 0.48 mmol) and ClCH2CN (3 mL, 47 mmol) were added; the
reaction was run under a continuous stream of argon.  After six hours, the volatiles were
removed in vacuo and the crude product was purified by flash chromatography (silica,
3/1/hexane/ethyl acetate) to give an orange oil (0.63 mg, 80% yield). 1H NMR (300 MHz,
CDCl3) ? = 1.41 (3H, s), 1.57 (3H, s), 1.85-2.04 (3H, m), 2.22-2.38 (1H, m), 3.94 (3H, s)
4.0 (3H, s), 4.54-4.58 (1H, m), 4.76 (2H, q), 5.51 (2H, dd), 6.93 (1H, s), 7.69 (1H, s).  13C
NMR (75 MHz, CDCl3) ? = 25.4, 26.4, 27.1, 39.4, 48.9, 56.4, 56.5, 60.5, 61.8, 64.2,
108.2, 109.9, 114.0, 128.3, 139.4, 148.0, 152.3, 153.8, 171.3.  MS Calcd for C19H23N3O8
421.4. Found: (ESI+) 422.0 [M+H+]+.
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4.1.1.4 dCA-NVOC-DL-5,5-dimethylproline
To a dry flask was added NVOC-5,5-dimethylproline cyanomethyl ester (25 mg,
0.06 mmol), dCA (20 mg), and 0.8 mL of dry DMF, and the reaction was stirred under
argon.  The reaction was monitored by reverse-phase HPLC.  After four hours, the
reaction was purified by semi-preparative reverse phase (C18) HPLC.  The appropriate
fractions were combined and lyophilized.  The white powder was dissolved in 10 mM
acetic acid and lyophilized. This step was repeated to yield a white fluffy powder (3.3
mg).  MS Calcd for C36H45N10O21P2 1016.75. Found: (ESI
+) 1017.8 [M+H+]+.
4.1.2 Mutagenesis and preparation of cRNA and Oocytes
Mutant 5-HT3A receptor subunits were developed using the eukaryotic expression
vector pcDNA 3.1 (InVitrogen, Abingdon, U.K.) containing the complete coding
sequence for the 5-HT3A(b) subunit from NIE-115 cells as previously described.
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Mutagenesis reactions were performed using the Kunkel method66, and confirmed by
DNA sequencing.  Wild type and mutant receptor subunit coding sequences were then
subcloned into pGEMHE plasmid.67  This was linearized with Nhe1 (New England
Biolabs) and cRNA synthesized using T7 mMESSAGE mMACHINE kit (Ambion).
Oocytes from Xenopus laevis were prepared and maintained according to standard
laboratory protocol.
4.1.3 Synthesis of tRNA and dCA-amino acids
Unnatural amino acids were chemically synthesized as nitroveratryloxycarbonyl
(NVOC) protected cyanomethyl esters and coupled to the dinucleotide dCA, which was
then enzymatically ligated to 74-mer THG73 tRNACUA as detailed previously 
68.
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Immediately prior to co-injection with mRNA, tRNA-aa was deprotected by photolysis 69.
Typically, 5 ng mRNA and 25 ng tRNA-aa were injected into Stage V-VI oocytes in a
total volume of 50 nl.  For control experiments, mRNA was injected 1) in the absence of
tRNA and 2) with the THG73 74-mer tRNA.  Electrophysiological experiments were
performed 18 to 36 hours post injection.
4.1.4 Characterization of mutant receptors
5-HT-induced currents were recorded from individual oocytes using two-electrode
voltage clamp with either a GeneClamp 500 amplifier or an OpusXpress system (Axon
Instruments, Inc., Union City, CA).  All experiments were performed at 22-25º C.
Serotonin (creatinine sulphate complex, Sigma) was stored as 25 mM aliquots at –80°C,
diluted in calcium-free ND96, and delivered to cells via computer-controlled perfusion
systems.  Glass microelectrodes were backfilled with 3 M KCl and had a resistance of
approximately 1 M?. The holding potential was –60 mV unless otherwise specified.  To
determine EC50s, 5-HT concentration-response data were fitted to the Hill equation, I =
(Imax[A]
n)/(EC50
n + [A]n),where Imax is the maximal peak current, [A] is the concentration of
agonist, and n is the Hill coefficient.
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Chapter 5. Miscellaneous studies
5.1 Introduction
This chapter contains several miscellaneous studies.  These studies represent work
that is either in its initial stages or yielded not so interesting results.  Two of the studies
related in this chapter examine aromatic residues at the ligand-binding site in the Cys
loop receptors.  These studies were done in collaboration with the Sarah Lummis group at
the University of Cambridge.  The first study describes investigations of Tyr 198 in the
gamma-amino butyric acid C receptor (GABAC).  This tyrosine aligns with Trp ?149 in
the nAChR, and the study of Tyr 198 represents ongoing efforts by our group to
characterize the nature of the cation-? interaction in ligand recognition at Cys loop
receptors.  The second study examines Phe 226 in 5-HT3R with a series of phenylalanine
analogs.  This residue aligns with Tyr 190 in the nAChR.  This study completes the
survey of the aromatic box in the 5-HT3R.  The final study considered in this chapter
represents initial efforts to incorporate a backbone thioamide via nonsense suppression
methods.  This project is now in the capable hands of Lori Lee.
5.2 GABAC studies
5.2.1 Background
GABA is the main inhibitory neurotransmitter in the nervous system where its
action is mediated by three classes of receptors: GABAA, GABAB, and GABAC.
1-3  The
GABAB receptor is a G-protein coupled receptor, while both GABAA and GABAC
receptors belong to the Cys loop family of ligand-gated ion channels (LGIC).  In contrast
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to the nAChR and 5-HT3R, these are anion-selective ion channels.  The GABAA receptor
is the major inhibitory LGIC in the peripheral and central nervous system.1  The GABAC
receptor is much less prominent and found primarily in the retina, with lower levels in the
brain and spinal cord.1, 4, 5  Three subunits for the GABAC receptor have thus far been
identified (?1-?3).  These can all form functional homomeric receptors, and the ?1 and
?2 subunits can coassemble to form heteromeric receptors. 2 The GABAC receptor
displays a distinct physiology and pharmacology from that of GABAA.  GABAC has a
higher sensitivity to GABA, does not desensitize, and is insensitive to benzodiazepines,
barbiturates, and bicuculline.6-10
5.1.2 The ligand-binding site
Based on homology to the nAChR and AChBP, the ligand-binding site in the
GABAC receptor is believed to be located at subunit interfaces with the primary ligand-
binding determinants being contributed by residues in five noncontiguous loops, labeled
A-E.1, 3  As with other receptors in the Cys loop family, there is a predominance of
aromatic residues at the GABAC binding site.  The x-ray crystal structure of AChBP
shows the configuration of these residues to be an ‘aromatic box’ (Figure 5.1a).11  In
GABAC, four of the five aromatics that comprise the box are conserved (Figure 5.1b).
Previous work by our group has demonstrated that the loop B tryptophans in the nAChR
(Trp ?149) and 5-HT3R (Trp 183) bind the respective agonists of these receptors via a
cation-? interaction.12, 13  Interestingly, the aligning residue in GABAC is Tyr 198.  In the
MOD-1 receptor, another member of the Cys loop family— the loop B residue is also a
tyrosine.  Here, however, research from our group has demonstrated that the cation-? site
is located in loop C at Trp 226.14  Like the nAChR and 5-HT3R, this loop C residue is a
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tyrosine (Tyr 241) in GABAC.  In fact, all residues that form the aromatic box in GABAC
are tyrosines (Figure 5.1b).  While the indole ring of tryptophan exhibits the greatest
affinity for cations among the standard aromatic residues, the phenolic side chain of
tyrosine is also capable of forming strong cation-? interactions.
(a) (b)
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Receptor
nAChR
AChBP
5-HT3R
MOD-1
GABAC
B
W149
W143
W183
Y180
Y198
C1
Y190
Y185
F226
Y221
Y241
C2
Y198
Y192
Y234
W226
Y247
D
W55
W53
W90
F83
Y102
Figure 5.1.   Residues at the ligand-binding site in Cys loop LGIC.  (a) The
aromatic box from the x-ray crystal structure of AChBP.  Residue numbering is for
muscle nAChR.  (b) Alignment of conserved residues in the aromatic box
contributed by loops B-D.  Red residues represent cation-? binding sites.
In the work presented here a series of fluorinated phenylalanines (4-F-Phe,
3,5-F2-Phe, 3,4,5-F3-Phe) is incorporated at position 198 of GABAC to probe the possible
role of this site in binding the ammonium center of GABA via a cation-? interaction
(Figure 5.2).  The cation-? interaction is a noncovalent binding interaction between the
negative electrostatic potential on the face of an aromatic ring and a cation, and as such,
is sensitive to perturbation of the ring’s electrostatic potential.15  Thus, the strength of the
cation-? interaction can be serially modulated by progressive fluorination of the aromatic
ring.
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Figure 5.2.   (a) Amino acids incorporated at Tyr 198 in GABAC using nonsense
suppression methods.  (b) Agonists discussed in the text.
5.1.3 Results and discussion
The unnatural and natural amino acids used in this study were incorporated at
position 198 of GABAC using in vivo nonsense suppression methods.
16, 17  The specific
GABAC subtype examined in these studies is the homomeric mouse receptor formed from
?1 subunits.  Initial studies focused on the important controls of nonsense suppression,
ensuring no functional receptors are produced in the absence of charged aminoacyl tRNA
and rescue of the wild type receptor by reintroduction of tyrosine.  Oocytes injected with
198 UAG-containing mRNA only or with UAG-containing mRNA and uncharged tRNA
did not show any inducible currents with application of 1?mM GABA, indicating that any
readthrough of the mRNA does not produce functional receptors.  Injection of oocytes
with 198 UAG-containing mRNA and tRNA-Tyr produced receptors with wild type
characteristics: EC50 values around 2.0 µM and Hill coefficients near 2.5 (Table 5.1).
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Incorporation of Phe at 198 leads to a 6-fold increase in EC50 (Figure 5.3 and
Table 5.1).  This is similar to previously published work, where the Phe 198 Tyr mutation
yielded an 11-fold increase in EC50.6  The role of the hydroxyl oxygen was assessed
using 4-MeO-Phe and 4-Br-Phe.  The unnatural amino acid 4-MeO-Phe maintains an
oxygen atom at the 4 position of the ring, which can act as a hydrogen-bond acceptor, but
cannot function as a hydrogen bond donor.  4-Br-Phe was used as a measure of the steric
requirements of this site.  The bromo group is larger than a hydroxyl group, but roughly
similar in size to the methoxy group.  In addition, 4-Br-Phe and 4-F-Phe bind cations
with comparable affinity.  Incorporation of 4-MeO-Phe and 4-Br-Phe at 198 resulted in 3-
and 4-fold increases in EC50, respectively.  Relative to Phe, these mutations show a partial
rescue of wild type function, suggesting that both the size of the substituent and the
presence of an oxygen at the 4 position of the ring are important.
Before discussing the results from incorporation of the fluorinated phenylalanine
series, several important details should be noted.  In studies examining tryptophan
cation-? sites, the baseline for evaluating the functional effects produced by fluorination
is the wild type receptor.12-14 Tyrosine, however, contains an ionizable hydroxyl group.
Fluorination of the phenol ring would lower the pKa of this group and could result in a
phenolate anion at this position.  Consequently, in considering tyrosine sites, it is
necessary to use the fluorinated phenylalanine series which eliminates this complication.
The baseline for evaluating the effects of fluorination in these studies, however, is the
phenylalanine mutant, and not the wild type residue.  This is a reasonable comparison, as
phenylalanine and tyrosine bind cations with similar affinity, and any effects arising from
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the absence of the hydroxyl group will likely be consistent across the series of
phenylalanine derivatives.
Table 5.1. Dose-response data for suppression at 198 in GABAC
Residue Cation-? binding
(kcal/mol)
EC50±SEM (µM) Hill±SEM
Tyr 26.9 2.1    ± 0.11 2.46 ± 0.25
Phe 27.1 14.0  ± 1.11 2.63 ± 0.43
4-F-Phe 22.0 33.5  ± 4.83 1.9   ± 0.29
F2Phe 17.1 1631 ± 96 1.95 ± 0.35
F3Phe 12.9 8550 ± 303 1.55 ± 0.18
4-Br-Phe 9.2    ± 0.08 0.68 ± 0.12
4-MeO-Phe 6.6    ± 0.05 0.66 ± 0.09
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Figure 5.3.   Dose-response relations for suppression experiments at 198 in
GABAC.  (a) Tyr (open circles), Phe (open squares), 4-F-Phe (open diamonds), F2Phe
(open triangles), and F3Phe (filled circles).  (b) Tyr (open circles), 4-Br-Phe (open squares),
4-MeO-Phe (open triangles)
The dose-response data for incorporation of the fluorinated phenylalanine series
shows a clear trend (Figure 5.3 and Table 5.1).  Each additional fluorine leads to a
concomitant rise in EC50.  As in previous work on the nAChR and 5-HT3R, our measure
for the cation-? binding ability of the fluorinated derivatives is the calculated binding
113
energy (kcal/mol) of a generic probe cation (Na+) to the corresponding substituted
benzene ring.12-14  Extensive studies of the cation-? interaction establish that trends in
cation-? binding ability across a series of aromatics are independent of the identity of the
cation, justifying the use of a simple probe ion.15  The calculations for Phe and 4-F-Phe
were performed by Sandro Mecozzi and Anthony West18, and the calculations for
3,5-F2-Phe and 3,4,5-F3-Phe were performed by Dennis Dougherty (unpublished results).
The fluorination plot (a plot of log EC50 versus the calculated cation binding ability of the
fluorinated derivatives; see Chapter 2 for details) for these data shows a compelling
relationship (Figure 5.4).  Over a range of greater than three orders of magnitude in EC50,
there is a linear correlation between log EC50 (using log EC50 to put the EC50 data on an
energy scale) and the cation-? binding ability of the side chains.  This provides
substantial evidence that Tyr 198 binds GABA through a cation-? interaction arising
from van der Waals contact between the agonist ammonium group and the aromatic side
chain.
These findings provide further evidence that the cation-? interaction is a common
recognition strategy for agonist binding in the Cys loop receptors.  Four members in this
family have now been shown to bind their respective ligands through a cation-?
interaction.12-14  Tyr 198 in GABAC represents the first tyrosine residue to be identified as
a cation-? site using fluorinated unnatural amino acids.  This study also emphasizes the
uniqueness of MOD-1, as GABAC follows the trend of the nAChR and the 5-HT3R with
the location of the cation-? site in loop B (Figure 5.1).  Inspection of the fluorination plot
in Figure 5.4b shows that the line for GABA has a similar slope as 5-HT (in both the 5-
HT3R and MOD-1).  This supports the idea that, given the large electrostatic component
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of the cation-? interaction, primary ammonium groups (Figure 5.2) are more sensitive to
electronic perturbation of their aromatic binding partner.12
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Figure 5.4.   Analysis of the cation-? studies in Cys loop LGIC.  (a) Fluorination
plot for fluoro-Phe series at 198 in GABAC (the equation for the linear fit is
y?=?5.5?-?0.21x).  (b) Fluorination plot for all LGICs with cation-? sites.  Two
different series of fluorinated aromatics are shown in this plot, thus the x-axis
reflects the relative binding affinity of each residue in a series.  For ACh, 5-HT,
and MOD-1 (also 5-HT but different receptor) the data points correspond to fluoro-
Trp series and right to left are:  Trp, FTrp, F2Trp, F3Trp, and F4Trp.  For GABA the
plot is for fluoro-Phe series and right to left are: Phe, Fphe, F2Phe, and F3Phe.
5.2 Phe 226 in the 5-HT3R
In the 5-HT3R, four of the five residues at the aromatic box are conserved (Figure
5.1).  In previous work (Chapter 2 and 3), we have examined all but Phe 226.12, 19  This
residue is located in loop C and aligns with Tyr 190 in the nAChR.  The functional role
of Phe 226 was examined using a series of phenylalanine analogs incorporated via
nonsense suppression methods (Figure 5.5).16, 17
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Figure 5.5.  Residues used in the study of Phe 226 in 5-HT3R
Reintroduction of phenylalanine at position 226 produced receptors with an EC50
value similar to wild type, 1.6 µM (Table 5.2).  Injection of mRNA alone or with
uncharged tRNA did not yield functional receptors.  The dose-response results for
substitution of Phe 226 indicate this is not an overly important position.  Incorporation of
4-Me-Phe or 4-Br-Phe leads to a 9-fold increase in EC50.  The similarity in results
observed for these two unnaturals suggests this increase in EC50 is likely a steric effect,
and not due to modulation of electrostatic potential on the aromatic ring.  This conclusion
is supported by the small increase in EC50 seen in the 4-F-Phe mutant (4-fold increase.)
Interestingly, incorporation of Tyr at 226 leads to a small decrease in EC50.  This group of
mutations shows Phe 226 is quite tolerant to a variety of substitutions at the 4 position of
the aromatic ring.
Table 5.2. Dose-response data for Suppression at 226
Residue EC50±SEM (µM)
Phe 1.6   ± 0.3
Tyr 1.0   ± 0.1
Ala 23.7 ± 5.3
4-Me-Phe 14.3 ± 3.2
4-Br-Phe 14.7 ± 2.4
4-F-Phe 7.1   ± 0.8
F3-Phe >300
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Two mutations did, however, lead to larger increases in EC50, Ala and F3-Phe.
These lead to 23- and >200-fold increases, respectively.  The fact that Ala was less
perturbing than F3Phe is noteworthy in that completely removing the ring has a smaller
effect than maintaining the steric size of the ring, but altering the electrostatic potential
on the ring.  It is also somewhat puzzling that electron–withdrawing groups at the 4
position of the ring are well tolerated, but either the combined effect of three such groups
in F3-Phe or their specific placement on the ring (at positions 3,4, and 5) leads to a large
perturbation in receptor function.  The latter possibility suggests a specific interaction
with one of the ring hydrogens at position 3 or 5.
In the homology model of the 5-HT3R with 5-HT computationally docked at the
binding site, the side chain of Phe 226 is located very near the indole ring of 5-HT
(Figure 5.6).20 The model does not, however, point to any special role for Phe 226.  The
findings at Phe 226 are quite distinct from what was observed at Tyr 190 in nAChR.21
Similar substitutions here ablate receptor function or cause large increases in EC50,
indicating both the hydroxyl and the aromatic group are critical.  These studies
demonstrate that there are subtle differences in the functional role of binding-site residues
among the receptors in the Cys loop family.
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Figure 5.6.  Homology model of the 5-HT3R with 5-HT computationally docked at
the ligand-binding site.  Phe 226 is shown in green.
5.3 Efforts towards the incorporation of a backbone thioamide
5.3.1 Background
A powerful use of the nonsense suppression method is the introduction of backbone
mutations.  To date, the method has proven amenable to the incorporation of esters, aza-
amides, and oxy-amides into the protein backbone (Figure 5.7a).22-24  These mutations can
be used to probe the hydrogen-bonding properties and local secondary structure at main
chain sites.  Thus far, the incorporation of backbone mutations has been limited to
modifications at the amide nitrogen.  Incorporation of a backbone thioamide group
represents a potential backbone mutation with modification at the amide oxygen (Figure
5.7b).
The thioamide group has been widely used in the solid-phase synthesis of small
peptides for peptidomimetic studies.25-32  Introduction of a thioamide into the main chain
of the protein alters the hydrogen-bonding properties of the protein backbone.33  Relative
to the standard peptide bond, the thioamide carbonyl is a weaker hydrogen-bond acceptor
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and the thioamide NH is a stronger hydrogen-bond donor.  Thus, in studies of backbone
hydrogen-bonding, the thioamide would be a useful complement to main chain ester
mutations which remove the hydrogen-bond donor at the amide nitrogen position.  In
addition, the increased C=S bond length (1.65 Å versus 1.2 Å for C=O) and larger van
der Waals radius of the sulfur atom (0.45 Å greater than oxygen) lead to a widening of
secondary structure and results in a loss of conformational freedom in the protein
backbone.31, 34, 35  Studies have demonstrated, however, that main chain thioamides do not
significantly destabilize ?-helices or ?-sheets.26, 27, 31  One particularly attractive feature of
the thioamide group is that substitution of oxygen by sulfur in an amide bond leads to
significantly red-shifted ???* and n-?* absorptions, lowering the excitation energy
needed for photoisomerization.  Recent studies have shown that cis/trans isomerization of
a thioamide group can be readily induced by 250-280 nm light.36  This latter feature could
be a potentially valuable tool for investigating protein conformational changes.
119
O
O
O
N
H
H
N
O
N
H
O
Ester
Aza-amide
Oxy-amide
O
N
HAmide
S
N
HThioamide
(a) (b)
Figure 5.7.   Protein backbone mutations.  (a) Backbone mutations thus far
incorporated by nonsense suppression.  (b) Electrostatic potential surfaces for an
amide and thioamide, illustrating the relative size of the two groups and the lesser
negative potential of sulfur relative to oxygen (red = negative, blue = positive).
5.3.2 Synthetic concerns
Thionation— the conversion of a carbonyl group to a thiocarbonyl— is a widely
used synthetic transformation for the preparation of organosulfur compounds.  Typically
this transformation is accomplished using either phosphorus pentasulfide (P4S10) or
Lawesson’s reagent (LR) (Figure 5.8).37-40  Both of these reagents have a similar
reactivity profile.  In general, the ease of thionation for a given substrate with these
reagents is determined by the electron density at the carbonyl oxygen.  Thus, the
thionation of amides is usually a fairly facile transformation, while thionation of esters
often requires elevated temperatures, longer reaction times, and generally results in poor
yields.  LR is more commonly used for the thionation of amides as it tends to give higher
yields with fewer side reactions.37  In the case of esters, both reagents have their
advantages and disadvantages.  The longer reaction times and higher temperatures
required for esters means that with either reagent there are significant side reactions.  One
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advantage of P4S10, however, is that many of the products from side reactions can be
removed through aqueous work-up.41  It should be noted, however, that because both
reagents have highly electrophillic phosphorus species, reactions with either reagent
require very dry conditions.
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Figure 5.8.   Thionation reagents.
Early work on the peptidyl-transfer reaction demonstrated that the ribosome can
catalyze the formation of a main chain thioamide in a growing peptide chain.42  This work
used a tRNA where the typical ester linkage between the tRNA and amino acid was
replaced by a thionoester— an ester in which the carbonyl oxygen is substituted with
sulfur.  This study provides evidence for the feasibility of using nonsense suppression to
incorporate a backbone thioamide.
The central challenge in realizing suppression-mediated thioamide incorporation is
the synthetic preparation of an amino-thionoacyl dCA, where analogous to the studies
above the amino acid and dinucleotide are linked by a thionoester (Figure 5.9).  There are
two important issues in considering synthetic approaches to this thionoester linkage.
First, the thionated residue must be activated in way that is compatible with dCA
coupling, and second, thionation of the residue must be synthetically accessible.  In solid-
phase peptide synthesis thioamides are introduced by replacing the carboxylic acid with
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an amide.28, 29, 43, 44  This is then thionated with LR and activated so that the amine is a
good leaving group during the peptide coupling reaction.  This strategy avoids having to
thionate the activated ester.  Adapting this protocol for use with the standard dCA
coupling chemistry used in preparation of aminoacyl dCA represents one possible
approach to generating aminoacyl dCA with a thionoester linkage (Scheme 5.1).43, 44  This
method, however, would require the development of new dCA coupling chemistry.  A
second approach to this problem is to thionate the activated cyanomethyl ester and then
couple the thionated ester with dCA (Scheme 5.2).  This route uses the standard dCA
coupling chemistry, but has the drawback of having to thionate an ester.
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Figure 5.9.   Schematic illustrating the ester linkage between the amino acid and
the dinucleotide dCA and the thionoester linkage with dCA that is necessary for
incorporation of a thioamide via nonsense suppression methods.
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Scheme 5.1.   Synthetic route to amino thionoacyl dCA, adapted from strategies
used in the solid-phase synthesis of peptides containing thioamides.
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5.3.3 Experiments
5.3.3.1 Synthesis of thionoNVOC-Pro cyanomethyl thionoester
Initial attempts to synthesize amino thionoacyl dCA followed the route shown in
Scheme 5.2.  In the end, it was decided that remaining with the standard chemistry used
in nonsense suppression represented a better strategy.  It is also a shorter route, as it
requires only one additional step to be added to the standard amino acid activation and
dCA coupling protocol.  It should be noted that carbamates are generally quite reactive
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with LR, and thus, it is anticipated that the NVOC carbonyl will also be thionated.37  This
does not seem to be problematic, as the thionated species should not substantially perturb
the photolysis reaction.  The first thionation reaction used NVOC-Pro cyanomethyl ester
as the substrate and LR as the thionating reagent.  Proline was selected for the potential
use of the thiono-analog in studies of the M2-M3 loop (Chapter 4).  NVOC-Pro
cyanomethyl ester was synthesized in the usual manner.
NVOC-Pro cyanomethyl ester (150 mg, 0.39 mmol) was placed in an oven-dried
flask.  To this was added 2 mL of dry toluene and 3.6 molar equivalents of LR (568 mg,
14 mmol).  The reaction was run under positive argon pressure, heated to reflux in an oil
bath, and stirred.  The reaction was stopped after 12 hours and applied directly to a flash
chromatography column (silica, hexanes/ethyl acetate 1:1).  NMR analysis of the column
fractions showed no product, but did reveal that the column fractions contained multiple
compounds.  The diagnostic assay for thionation of an ester is 13C NMR.30  Thionation
leads to ~30 ppm upfield shift in the carbonyl carbon signal.  A very typical 13C chemical
shift for the carbonyl carbon in a cyanomethyl ester is ~170 ppm.  Thus it was expected
the product would show a peak near 200 ppm.  Thionation of an ester does not typically
lead to diagnostic chemical shifts in the 1H NMR spectrum.
The reaction was repeated using identical conditions.  This time, however, the
reaction was monitored by reverse-phase HPLC and UV spectroscopy.  Purification was
carried out using semi-preparative reverse-phase HPLC.  The chromatogram showed two
peaks with significant 350?nm absorption (NVOC group).  One matched the elution
profile of NVOC-Pro cyanomethyl ester.  Fractions corresponding to the other peak were
isolated and lyophilized yielding a yellow/brown powder (24 mg, 14% yield).  1H NMR
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(300 MHz, CDCl3) ? = 1.95-2.04 (4H, m), 2.21-2.29 (2H, m), 3.88 (3H, s) 3.90 (3H, s),
4.33-4.37 (1H, m), 4.97 (2H, q), 5.45 (2H, dd), 6.88 (1H, s), 7.63 (1H, s).  13C NMR (75
MHz, CDCl3) ? = 25.4, 30.4, 30.8, 47.3, 56.1, 57.4, 60.5, 65.7, 69.8, 108.3, 110.2, 128.3,
140.8, 148.6, 154.3, 156.2, 172.3.  MS Calcd for C17H19N3O6S2 425.48. Found: (ESI
+)
426.8 [M+H+]+.
The mass spectroscopy data correspond to thionoNVOC-Pro cyanomethyl
thionoester, with thionation at both the ester carbonyl and the carbamate carbonyl as was
expected.  Interestingly, the 13C data do not show a shift in the carbonyl carbon peaks for
the ester or the carbamate, 172.3 and 156.2 ppm, respectively.  The corresponding peaks
in NVOC-Pro cyanomethyl ester for the ester and carbamate carbons are 171.9 and 155.4
ppm, respectively.  The 13C and 1H NMR spectra do show differences in the chemical
shifts between the two compounds, but the origin of these differences was not able to be
determined.  Ultimately the spectral data are ambiguous as to the identity of the isolated
product.  The mass spectroscopy analysis indicates it is thionoNVOC-Pro cyanomethyl
thionoester, but the 13C NMR data do not show the diagnostic shifts.  Despite this
uncertainty, the product was taken on to the dCA coupling step.  For comparison the
spectral data for NVOC-Pro cyanomethyl ester are shown below: 1H NMR (300 MHz,
CDCl3) ? = 1.68-1.88 (4H, m), 2.07-2.15 (2H, m), 3.69 (3H, s) 3.77 (3H, s), 4.20-4.23
(1H, m), 4.59 (2H, q), 5.25 (2H, dd), 6.74 (1H, s), 7.42 (1H, s).  13C NMR (75 MHz,
CDCl3) ? = 24.7, 29.5, 31.0, 36.3, 49.8, 54.3, 56.2, 58.8, 64.8, 110.1, 114.2, 128.7, 139.8,
148.4, 154.3, 155.4, 171.9.  MS Calcd for C17H19N3O8 393.35. Found: (ESI
+) 394.4
[M+H+]+
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5.3.3.2 dCA coupling
Coupling of the speculative thionoNVOC-Pro cyanomethyl thionoester to dCA
was done in the usual manner.  To a dry flask was added thionoNVOC-Pro cyanomethyl
thionoester (24 mg, 0.056 mmol), dCA (20 mg), and 0.8 mL of dry DMF, and the
reaction was stirred under argon.  The reaction was monitored by reverse-phase HPLC.
After 6 hours no product formation was seen, so tetrabutylammonium acetate (10 mg)
was added to the reaction.  The reaction immediately turned scarlet red.  After 48 hours
no product formation was observed and the chromatogram for the reaction showed a
multitude of side reactions.
5.3.3.3 Attempts using microwave irradiation
The reactions detailed above revealed several problems with the initial strategy.
The reactions showed a significant number of side reactions.  The use of excess LR as is
required in the thionation of esters made the purification problematic by either flash
chromatography (insufficient purification) or reverse-phase HPLC (time consuming), and
ultimately, the results were ambiguous.37  Recently, several groups have reported facile
thionation of esters using solvent-free microwave reactions.45, 46  These studies reported
high yields, required only minutes to run, and were able to thionate recalcitrant
substrates.  These studies also adapted a procedure commonly used in P4S10 thionations,
where it has been noted that inclusion of the scavenger hexamethyl-disiloxane (HMDO)
in the reaction mix reduces the number of side products and improves the yield.38, 41
For the solvent-free microwave-assisted reactions described below, NVOC-Gly
cyano methyl ester was used as the substrate.  This was done to simplify the NMR
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spectra and for potential proof of principle experiments involving the Shaker potassium
channel (discussed in 5.3.4 Future directions).
In the first reaction, NVOC-Gly cyanomethyl ester (100 mg, 0.28 mmol) and LR
(183 mg, 0.45 mmol) were placed in a test tube and thoroughly mixed with a spatula.
The test tube was placed in an alumina bath (alumina in a beaker) and irradiated with an
unmodified household microwave at maximum wattage (1000 W) for 3 minutes
(continuous radiation).  This reaction yielded black charred material.  The second
reaction was set up in an identical manner and irradiated for 5 minutes (10 x 30 s).
Following irradiation, the reaction mix was dissolved in methylene chloride and loaded
on a flash chromatography column (silica, hexanes/ethyl acetate 1:1).  Neither product
nor starting material was isolated.  In the third attempt, HMDO (73 mg, 95 µL, 0.45
mmol) was included in the reaction mix and the reaction was irradiated for 5 min. (10 x
30 s).  Again, neither products nor starting materials were isolated by flash
chromatography.
5.3.4 Future directions
There are several possible directions that can be taken to address the problems
encountered in trying to synthesize amino thionoacyl dCA.  The first is the use of model
compounds.  This would allow a better estimation of the proper reaction conditions.  As
noted in the introductory section, thionation reactions with LR or P4S10 are very sensitive
to water.  It may be that the conditions were not dry enough.  In addition, the reactions
were run with 3.6 molar equivalents of LR.  This excess— although standard in
thionations of esters— certainly must lead to more side products as well as making
purification in general more difficult.37, 39  It would also be worthwhile to include HMDO
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in the standard LR reactions, and reactions using P4S10 should be considered.  If none of
these steps prove sufficient, then the route illustrated in Scheme 5.1 offers an alternative
that avoids having to thionate an ester.
Once the synthetic issues are worked out, the early studies on the peptidyl-transfer
reaction indicate this mutation is compatible with the ribosome and thus, should be
amenable to incorporation by nonsense suppression methods.  Once incorporated into the
protein, backbone thioamides can be readily cleaved by treatment with trifluoracetic
acid.47  The mechanism for this cleavage proceeds in a similar manner to the Edman
degradation.  This would provide a direct means for verifying the successful
incorporation of a backbone thioamide, as the full-length protein and the cleaved protein
would show different gel mobilities.  Finally, a nice proof of principle experiment would
be the incorporation of a thionoGly at the selectivity filter of the Shaker potassium
channel.  The selectivity filter in potassium channels is composed of several backbone
carbonyls that point into the channel lumen.  The carbonyl oxygen atoms serve to
coordinate the potassium ion as it enters the channel.  Thus, replacement of the oxygens
with the less electronegative sulfur atom should alter the ion selectivity and permeation
properties of these channels.
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